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i. Abstract 
Background: Metabolic associated fatty liver disease (MAFLD) afflicts about a quarter of the 
global population. A proportion of these patients develop chronic inflammation which can 
progress to cirrhosis and cancer. Sugar consumption is a major risk factor of MAFLD 
progression and a human FGF21 variant (rs838133) was recently found to be a risk variant for 
increased sugar consumption. Whether this variant is a novel risk factor for MAFLD is 
unknown.  
Methods: We studied the association of FGF21 rs838133 with liver disease severity and the 
metabolic profile of patients with MAFLD. Functional investigations were undertaken using 
allele-specific expression of FGF21 in liver, by measurement of serum FGF21 by ELIZA, 
bioinformatics analysis and by complementary mouse studies. 
Results: FGF21 rs838133 was associated with an increased risk of metabolic associated 
steatohepatitis (MASH), but not simple steatosis. The variant did not affect hepatic FGF21 
expression or splicing, but likely affects FGF21 mRNA structure. Compared to healthy 
controls, patients with MAFLD have higher serum FGF21 levels (p < 0.05). This difference 
was more profound in patients with MASH (162 ± 47.26, p < 0.01) compared to those with 
simple steatosis (155.2 ± 51.98, p < 0.01). Similarly, FGF21 levels increased with progression 
of the NAS score and with fibrosis (p <0.05, for both). Consistently, there was a positive 
correlation between FGF21 levels and blood glucose, HOMA-IR, AST, GGT, triglycerides, 
total bile acids and primary bile acids (p < 0.05, for all). In mouse models of liver injury, Fgf21 
expression was increased by a high sucrose diet, and in two liver injury models, namely bile 
duct ligation (p < 0.05, for both) and a methionine and choline deficient diet (p < 0.0001). 
There was no correlation between serum levels of FGF21 and other FGF family proteins 
(FGF19, FGF23).   
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Conclusion: FGF21 rs838133 is a novel risk variant for MASH, likely via a change in mRNA 
folding and subsequently, stability. FGF21 serum levels are likely increased in MASH due to 
hepatic resistance and correlates with markers of glycaemic profile and bile acids in these 
patients. Different members of the FGF family of proteins are likely regulated by different 
mechanisms. 
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1.1 Burden of chronic liver disease globally and in Australia  
Chronic liver diseases (CLDs) represent a major but underestimated global public 
health burden. A recent estimate shows that 844 million people have CLDs with a mortality 
rate of 2 million deaths per year [1]. In Australia, CLD is the 5th most common cause of death 
with financial costs estimated at $5.4 billion and affects around one third of the population. 
This can be compared with other major public health problems related to chronic diseases such 
as pulmonary disease (650 million affected, 6.17 million deaths annually), cardiovascular 
diseases (540 million, 17.7 million deaths) and diabetes (422 million, 1.6 million deaths) [1]. 
A recent report also noted that in contrast to congestive heart failure or chronic obstructive 
pulmonary disease, patients with CLD had higher rates of hospitalization, longer hospital stays, 
more readmissions, and less access to intensive care [2]. It was estimated that liver disease will 
surpass ischaemic heart disease as the main source of years of working life lost [3]. 
The major causes of CLD are viral hepatitis (chronic hepatitis B and chronic hepatitis 
C), alcoholic fatty liver disease and metabolic associated fatty Liver disease (MAFLD; 
previously known as non-alcoholic fatty liver disease [NAFLD]). With the availability of 
effective hepatitis B virus vaccination and treatment and the revolutionary changes in the 
landscape of hepatitis C virus treatment with the new generation direct anti-viral drugs, viral 
hepatitis is declining as a major cause of CLD [1]. Instead, MAFLD is emerging as the major 
cause of chronic liver disease around the world [4], in parallel with increasing obesity and 
diabetes prevalence. 
Obesity prevalence is growing rapidly and becoming one of the most serious public 
health problems of the 21st century. A World Health Organization (WHO) global estimate 
noted that the prevalence of obesity has nearly tripled between 1975 and 2016 and about 13% 
of the world’s adult population (11% of males and 15% of females) were obese in 2016. The 
  3  
 
number of people with diabetes has likewise risen from 108 million in 1980 to 422 million in 
2014[5]. This increase in prevalence is due to increased consumption of more energy-dense, 
nutrient-poor foods with high levels of sugar and saturated fats, combined with reduced 
physical activity [6]. The worldwide prevalence of inadequate physical activity reported on 
trends from 2001 to 2016 was 27.5%, which was similar to the prevalence of inadequate 
physical activity in 2001 (28.5%) [7]. High-income Western nations were found to have the 
most significant levels of deficient physical activity (42.3%), whereas Southeast Asia (17.6%) 
and sub-Saharan African countries (17.9%) had the least prevalence [7]. Among countries that 
had the lowest income, insufficient physical activity prevalence was found to be half of that in 
high-income countries 16.5% and 36.8%, respectively [7]. In 2018, the WHO propelled an 
initiative to decrease the prevalence of physical activity by 10% and 15% by 2025 and 2030, 
respectively [8]. 
1.2 Epidemiology of MAFLD 
The global prevalence of MAFLD has been reported as high as 25.2% (Figure 1.1) [9], 
and is expected to increase by 2030 to 33.5% [10]. The prevalence of MAFLD varies widely 
by region, ethnicity, socioeconomic status, age, and gender. Although MAFLD is globally 
prevalent, the highest rates are reported from the Middle East, South America and Asia, where 
the prevalence was 32%, 31%, and 27%, respectively, followed by the USA (24%) and Europe 
(23%), while in Africa, MAFLD is less common (14%) [9, 11]. Younossi et al. in a meta-
analysis reported that MAFLD prevalence in Europe varies from 5% to 44% in different 
countries [12]. The prevalence in Germany is approximately 30% [13], while the prevalence is 
26.8% in France as determined by liver biopsies [12], and the prevalence in the UK was 26.4% 
[13]. In the Asia-Pacific region, different environmental factors could explain the disparities in 
the prevalence of MAFLD in different regions. In India, the prevalence is higher in urban 
(ranges from 16% to 32%) than in rural populations (9%) [14]. The same disparities between 
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rural and urban regions have been noted in other Asian countries for example, China, Sri Lanka 
and Malaysia [15]. Furthermore, MAFLD prevalence can vary among different ethnic groups. 
It has been reported that the prevalence of MAFLD is highest in Hispanic Americans, followed 
by European and African Americans [12], which may in part be explained by genetic factors, 
as will be discussed below.    
 
Figure 1. 1: Worldwide estimated prevalence of MAFLD and distribution of PNPLA3 genotypes. 
Figure 1.1: Worldwide estimated prevalence of MAFLD and distribution of the PNPLA3 
genotypes [12].    
Notably, recent projections using Markov models suggest that the estimated metabolic 
associated steatohepatitis (MASH) prevalence within the MAFLD population will continue to 
increase over the coming decades across many geographic regions. For example, the burden of 
MAFLD-related disease progression has been estimated in eight countries form 2016-2030 
[16]. In this model, in 2016 the prevalence of MAFLD ranged from 10.53 million in Spain to 
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243.67 million in China. By 2030, the maximum MAFLD prevalence was estimated in Italy 
(29.5%) and the lowest in France (23.6%). Similarly, the estimated MASH prevalence within 
the MAFLD population will increase in the incoming decades [16]. This modelling thus 
demonstrates slow growth in the total number of MAFLD cases but a greater increase in cases 
with advanced fibrosis [16]. Also, in a previous study using a Markov Model, there was a 
projected increase in MAFLD-related cirrhosis, advanced liver disease, and liver-related 
mortality through 2030 in the United States; projected to be almost 800,000 excess liver deaths 
through 2015-2030 [10].  
Hence, MAFLD represents a challenge to health care systems with a substantial 
economic burden. A steady-state prevalence model was recently built by Younossi and 
colleagues using a series of interlinked Markov chains to quantify the economic burden in the 
United States and Europe [17]. In this model in the United States, more than 64 million people 
were projected to have MAFLD with annual direct medical costs of around $103 billion 
($1,613 per patient), whereas in four European countries (United Kingdom, Germany, France, 
and Italy), there were ~52 million people with MAFLD with an annual cost of €35 billion (from 
€354 to €1,163 per patient) [17].  
1.2.1 Lean MAFLD: a common but less recognised group 
People suffering from metabolic disorders such as type 2 diabetes mellitus (T2DM), 
obesity and metabolic syndrome are at higher risk to develop MAFLD than the general 
population. Currently, it is estimated that 80% of MASH patients are obese, 44% have T2DM, 
and 72% are at risk of dyslipidaemia [9]. Having said this, MAFLD also occurs in non-obese 
and lean individuals based on the WHO recommendations for a definition of ‘lean’ which is a 
BMI < 25 kg m−2 for Caucasians and < 23 kg m−2 for Asians; similar cut-offs for the non-obese 
are BMI < 30 kg m−2 for Caucasians and < 25 kg m−2 for Asians [18]. A recent meta-analysis 
examined the overall prevalence of MAFLD from a total of 45 studies with 55,936 lean/non-
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obese patients. MAFLD prevalence was 10.2% in the lean population compared to 15.7% in 
the non-obese population [19]. However, MAFLD prevalence in the lean or non-obese 
population was suggested to be higher in western compared to eastern studies[19]. Within the 
lean MAFLD group, nearly 20% have MASH [20].  
Patients with lean MAFLD are at high risk of liver related complications, 
cardiovascular disease and diabetes compared to the general population [21], with some reports 
suggesting that they might even be at higher risk than their obese counterparts [22]; this 
however remains controversial.    
1.2.2 Spectrum and natural history of MAFLD 
MAFLD is considered as the hepatic manifestation of the metabolic syndrome and is 
currently defined as fat deposition in the liver in at least 5% of hepatocytes in people who do 
not consume excess alcohol or have any other liver disease [23, 24]. However, more recently, 
experts in the field suggest that a diagnosis of MAFLD should be independent of alcohol intake 
[25].  
The spectrum of MAFLD ranges from simple steatosis to steatosis with hepatocyte 
injury (ballooning), inflammation, and metabolic associated steatohepatitis (MASH); the latter 
can lead to fibrosis, cirrhosis, liver failure and hepatocellular carcinoma (HCC) [26, 27].  
Notably, only a small proportion of patients with MAFLD will develop MASH and this 
transition from isolated steatosis to MASH is a detrimental step in the course of the disease.  
MASH is considered to be a more severe form of the disease with a substantial risk of 
progression to advanced fibrosis and liver and non-liver-related mortality [28]. Factors 
involved in mediating this transition are not clear but their identification will have a huge 
translational impact.    
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1.2.3 The deleterious impact of MAFLD 
The deleterious impact of MAFLD is multifaceted. MAFLD is a leading cause for end-
stage liver disease, cancer and liver transplantation and it is projected that 20 million patients 
worldwide with MAFLD, will ultimately die of liver disease [29]. Cirrhosis develops in 4% to 
25% of MASH patients [30]. Once developed, 25% of these patients succumb to 
decompensation over a 10-year period as shown in Figure 1.2. Strong evidence also suggests 
that the severity of liver fibrosis is the major determinant of all MAFLD related complications 
[30]. 
In addition, MAFLD is currently the primary cause of hepatocellular carcinoma (HCC) 
in many countries including the UK [31]. Similarly, in the US, MAFLD-related HCC has 
demonstrated a 9% annual increase [32]. In a recent study based on 296,707 MAFLD patients 
with matched controls from the U.S. national Veterans Health Administration system, MAFLD 
had a > 7 fold increased risk of HCC compared to controls [33]. In another European study 
presented at EASL 2018, MAFLD and MASH patients had 5.83 and 22.67 fold increase risk 
of cirrhosis compared to controls, respectively [34]. In the same study, MAFLD and MASH 
patients had 3.15 and 8 fold increase risk of HCC compared to controls, respectively [34]. 
Notably, a recent prediction model has suggested that in affluent nations, prevalent HCC cases 
related to MAFLD will increase, ranging from increases of 47% in Japan to 130% in the US 
[10, 16]. Furthermore, HCC in MAFLD have a worse survival compared to HCC related to 
other aetiologies and are less likely to have curative therapies [35] perhaps because of their late 
presentation [36, 37]. HCC classically emerges in the setting of cirrhosis; however, ~20% of 
HCC’s have been known to develop in a non-cirrhotic liver [38, 39]. 
MAFLD related liver transplantation has likewise increased by 170% and is major 
indication for liver transplantation in patients aged < 50 years and is expected to the primary 
indication for liver transplantation by 2030 [37, 40]. 
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The clinical consequences of MAFLD are not limited to liver but also includes  
various extrahepatic comorbidities including cardiovascular diseases, T2DM, chronic kidney 
disease [41, 42], colorectal cancer, obstructive sleep apnoea, polycystic ovarian syndrome, 
osteoporosis, psoriasis, hypothyroidism, and iron overload [43].  
 
Figure 1. 2: Global burden and natural history of non-alcoholic fatty liver disease [43]. 
Figure 1.2: Global burden and natural history of non-alcoholic fatty liver disease [44]. 
1.3 Pathophysiology of MAFLD 
The pathophysiology of MAFLD and MASH are complex and likely the outcome of 
interactions between environmental, genetic and epigenetic factors [23].  
1.3.1 Genetic factors 
A large body of evidence suggests that MAFLD is a highly heritable disease. Family 
studies reveal that first degree relatives of patients with MAFLD are at a high risk of the disease 
than the general population [45, 46]. Similarly, family members of offspring with MAFLD 
should be considered at high risk for MAFLD, even in the absence of obesity or increased 
serum amino transferase levels [45]. Also, a very recent study that included 785 offspring with 
at least one parent from the multi-generational Framingham Heart Study suggests that 
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individuals with a parental history of hepatic steatosis are at increased risk for hepatic steatosis 
[46]. Furthermore, another twin based study that included 60 pairs of twins (42 monozygotic 
and 18 dizygotic) assessed the heritability of hepatic steatosis (based on magnetic resonance 
imaging-derived proton density fat fraction) was 0.52 and the heritability of hepatic fibrosis 
(based on liver stiffness) was 0.5 [47].  
Other evidence of heritability of MAFLD comes from epidemiological studies that 
demonstrate large inter-individual and interethnic variability in susceptibility to MAFLD and 
progression to MASH. Indeed, Hispanic Americans are at higher risk than those of European 
descent, whereas those of African-descent are protected from these conditions irrespective of 
adiposity, insulin resistance, and socioeconomic factors [48, 49] further suggesting a critical 
role for genetic predisposition. 
Broadly there are two main approaches for studying the genetic basis of a diseases. 
Hypothesis-driven, candidate gene studies and hypothesis-free, genome-wide association 
studies (GWAS). The first GWAS study was conducted in 2005 for macular degeneration and 
first GWAS in hepatology was in 2008 for MAFLD [50, 51]. The last decade have witnessed 
multiple GWAS and large candidate gene studies which have enriched our understanding of 
the genetic basis of MAFLD [52]. 
There are at least five common genetic variants in five different genes robustly 
associated with the development and progression of MAFLD. They include the phospholipase 
domain-containing protein 3 (PNPLA3) isoleucine to methionine substitution at position 148 
(rs738409 C>G encoding for PNPLA3 I148M)[53], Transmembrane 6 superfamily member 2 
(TM6SF2) ( rs58542926 C>T encoding for an E to K substitution at position 167 resulting in a 
loss-of-function)[54-56], Membrane bound O-acyltransferase domain-containing 7 (MBOAT7) 
(rs641738 C>T variant linked to the 3′ untranslated region of MBOAT7)[57, 58], glucokinase 
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regulator (GCKR) (rs1260326, a common missense loss-of-function GCKR mutation encoding 
for the P446L protein variant) and most recently, the hepatic lipid droplet protein 
hydroxysteroid 17-beta dehydrogenase 13  (HSD17B13) ( rs72613567:TA, affecting splicing) 
[59].  
Other variants reported to play an important role in the progression of MAFLD include 
variants in the interferon lambda 3/4 region that regulates innate immunity in the liver [60]. A 
recent study has suggested that interferon lambda 3 is the causative protein of this haplotype 
association with liver inflammation and fibrosis [61]. Another variant is in the MER proto-
oncogene, tyrosine kinase (MERTK) gene that seems to be an important player in hepatic 
stellate cell activation and also in the regulation of efferocytosis by immune cells [62]. The 
major pathways involved in the susceptibility towards MAFLD and gene loci robustly 
associated with its development and progression are summarised in Figure 1.3. 
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e 1. 3: Major pathways involved in the susceptibility towards MAFLD and gene loci robustly associated with development and 
progression of the disease. 
 
Figure 1.3: Major pathways involved in the susceptibility towards MAFLD and gene loci 
robustly associated with development and progression of the disease. APOB, 
apolipoprotein B; IFN-λ3, interferon lambda 3; GCKR, glucokinase regulatory gene; HSC, 
hepatic stellate cell; LIPA, lysosomal acid lipase; MTTP, microsomal triglyceride transfer 
protein; PNPLA3, patatin-like phospholipase domain-containing protein 3; SOD2, superoxide 
dismutase 2; TM6SF2, transmembrane 6 superfamily member 2 TRIB1, tribble-1 UCP2, 
Uncoupling protein 2; VLDL, very low density lipoprotein[49]. 
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While well designed published GWAS and candidate gene studies have enriched our 
understanding of the genetic basis of individual variation in liver disease progression, a major 
challenge remains that the known loci of all complex phenotypes tend to explain only a tiny 
proportion of the heritability of the phenotype [63]. The same is true for complex diseases with 
high heritability such as age-related macular degeneration [64, 65]. Thus, a significant 
proportion of the fibrosis progression rate cannot be explained by common cofactors including 
clinical variables and SNPs discovered by GWAS based on a low pseudo-R2 of the multivariate 
logistic regression model for fibrosis progression [66]. This observation indicates that there are 
additional loci, other types of genetic variation and non-sequence based genomic variation 
affecting liver injury that remains to be uncovered. Further studies are required to tackle this 
challenge and unidentified genetic and epigenetic variations likely exist to explain the missing 
heritability. 
1.3.2 Environmental Factors 
Unhealthy dietary patterns and decrease physical activity are the main proximate causes 
of non-communicable diseases such as obesity, T2DM and MAFLD [67-69]. Below, I discuss 
the role of dietary factors in MAFLD relevant to my thesis.  
1.3.2.1 Macronutrients and MAFLD 
Fructose and sweetened beverages 
Fructose is a sugar found naturally in fruits, fruit juices, some vegetables and honey. In 
addition, it is a basic component of table sugar (sucrose is a disaccharide of fructose and 
glucose). High-fructose corn syrup, a mixture of fructose and glucose monosaccharides is used 
to sweeten many processed foods and beverages [70]. Intake of fructose has expanded over the 
last few years in parallel with the increased intake of sucrose and high-fructose corn syrup; at 
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present the consumption of sugars approaches 15% of overall energy consumption in the 
western eating regimen [71].  
Commonly, MAFLD patients consume high caloric diets especially in the form of sugar 
compared to the general population as illustrated in Table 1.1 [72]. Fructose and sugar 
sweetened beverage drink consumption is strongly associated with MAFLD in humans [73-
75]. The administration of sugary beverages for six months to people results in increased 
hepatic fat as confirmed by magnetic resonance spectroscopy [76]. On the other hand, the 
limitation of fructose intake for 9 days in children leads to a decrease in liver fat, in de-novo 
lipogenesis [77] and an improvement in components of the metabolic syndrome including 
diastolic blood pressure, serum triglycerides and insulin resistance [78]. Tendler et al, studied 
the effect of a low-carbohydrate diet (< 20 g/d) on hepatic steatosis in five patients with 
MAFLD; after 6 months, repeat liver biopsies demonstrated a decrease in steatosis, 
inflammation, fibrosis, and a weight reduction of 12.8 kg [79]. 
  A possible explanation might be that fructose is taken up by the liver and metabolised 
to the triose-phosphate independently of insulin and without any input by ATP or citrate. Most 
fructose is transformed into glucose which can then be released to the blood or stored as 
glycogen. A proportion is transformed into lactate. In addition, the liver is responsible for the 
conversion of excess carbohydrates from diet to triglycerides through de-novo lipogenesis 
(DNL), a complex and highly regulated process that is regulated by glucose and insulin [37]. 
The hepatic steatosis in MAFLD patients results from increased de novo lipogenesis, decreased 
export of hepatic lipid and reduced FFA oxidation [85-87]. Notably, hereditary predisposition 
may play a role in the inter-individual variation in fructose utilization and related liver disease 
[80] but these are yet to be well clarified.  
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Mechanistically, animal studies demonstrate the effects of fructose intake on promoting 
hepatic steatosis and include through decreased PPAR alpha activity-mediated hepatic lipid 
oxidation and stimulation of the NF-kB signalling pathways that leads to oxidative stress, 
hepatic steatosis and hepatic fibrosis [81]. The effect of high fructose on increasing leptin 
secretion and oxidative stress in plasma and tissues is another suggested mechanism [82].  
Table 1.1: Soft drink consumption in patients with MAFLD and healthy controls [72]. 
 
Dietary constituent MAFLD  
(n = 31) 
Controls  
(n = 30) 
p value 
Total energy intake (Kcal) 2300 ± 500 2200 ± 600 0.3 
Added sugar (g/d) 75.6 ± 8.4 33.6 ± 12.6 0.001 
Percent of added sugar from soft drinks   43% 8% 0.011 
Table 1. 1 Soft drink consumption in patients with MAFLD and healthy controls. 
Data are presented as mean ± SD. 
Dietary fat  
MAFLD patients have higher intake of dietary fat. For instance, a study by Musso et 
al. comparing the dietary pattern of MAFLD patients and healthy individuals demonstrated 
that the former tend to have a higher intake of saturated fat and cholesterol and less 
polyunsaturated fatty acids than the latter [83]. Another study by Cortez-Pinto et al. revealed a 
higher monounsaturated fatty acid intake in MAFLD patients compared to controls [84]. 
Similarly Rietman et al. demonstrated that monounsaturated fatty acid and total fat intake were 
positively correlated with a higher fatty liver index score [85]. It follows that current dietary 
recommendations for patients with MAFLD suggest avoiding highly processed food products 
enriched with trans-fatty acids and omega-6 [86, 87].  
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      There are several plausible mechanistic explanations for the effects of a high fat diet in 
prompting hepatic steatosis [88]. Fat deposition activates lipolysis in adipocytes and elevates 
FFAs that result in decreased plasma adiponectin levels, reduced lipid removal from plasma 
and raised muscle beta-oxidation [89]. High fat diet feeding in a MASH rabbit model likewise 
increases body weight, liver weight, alanine aminotransferase (ALT), triglycerides, interleukin 
6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels, whereas it reduces serum adiponectin 
and interleukin 10  levels [90-92]. In rats, saturated fatty acids activate endoplasmic reticulum 
(ER) stress and hepatocyte injury [93]. Similarly, saturated fat consumption is associated with 
hindered glutathione metabolism promoting oxidative stress and progression of MAFLD [94].  
However, not all fat is the same. For example, omega-3 and polyunsaturated fatty acids 
have been demonstrated to play a beneficial role in the pathogenesis of MAFLD [87]. Omega-
3 fatty acids also increase anti-inflammatory mediators leading to an improvement of insulin 
sensitivity that then induces triglyceride redistribution [95, 96]. Docosahexaenoic acid, 
linolenic acid (plant oil), and eicosapentaenoic acid [fish oil] are sources of omega-3 fatty acids 
[97]. Recently, it has been suggested that docosahexaenoic acid can decrease MAFLD in 
HepG2 cells by reducing lipid deposition [98]. 
1.3.2.2 Insulin Resistance  
Insulin resistance has an intimate chicken-and-egg relationship with hepatic lipid 
accumulation. There is a strong evidence to suggest that insulin resistance is the central 
mediating factor in the pathogenesis of MAFLD and vice versa [99]. Visceral fat rather than 
overall adiposity correlates with liver function and predicts hepatic steatosis [100, 101]. 
Visceral fat accumulation causes hepatic insulin resistance and inflammation, release of 
lipotoxic hepatocyte apoptotic bodies with subsequent Kupffer cell and hepatic stellate cell 
activation; the latter leads to increased collagen matrix production prompting liver disease 
progression as illustrated in Figure 1.4 [42]. Furthermore, in MAFLD, diabetogenic 
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hepatokine secretion, for instance, retinol binding protein-4, fetuin-A, as well as inflammatory 
biomarker secretion including of TNF-α, IL-6 and C-reactive protein may influence insulin 
signalling, hepatic gluconeogenesis and glycogen synthesis [102-105]. A pivotal role for 
fibroblast growth factor 21 (FGF21) is also emerging as discussed in detail below. 
1.3.2.3 Adipocytokines and myokines 
The adipocyte is the functional unit of adipose tissue performing a central role in lipid 
uptake and storage [106]. Adipocytes are currently considered an endocrine organ [107, 
108].With adipocyte differentiation and increased fat mass, the cells secrete numerous 
cytokines [109, 110] such as resistin [111], angiotensinogen [112, 113], TNF- α [114], and 
FFAs [115]. While serum leptin is increased in MAFLD [116], plasma adiponectin levels 
decrease with obesity, T2DM and MAFLD, irrespective of the the expansion of fat mass [117, 
118], suggesting the presence of hepatocyte leptin resistance.  
Functionally, adiponectin increases fatty acid oxidation through adenosine 
monophosphate-activated protein kinase (AMPK) and suppresses gluconeogenesis, both in 
turn improves insulin sensitivity [119, 120]. Serum levels of leptin associate with hepatic 
steatosis but not with inflammation or fibrosis, which reflect its pathogenic role in hepatic 
insulin resistance [121]. In addition, inflammatory cytokines, such as TNF-α are also raised in 
diabetic, obese and MAFLD patients and might be implicated in the pathogenesis of the disease 
[122, 123]. Human FNDC5 is produced mainly by muscles however, it acts as a myokine and 
adipokine [124]. Recently, irisin has emerged as playing a beneficial metabolic effect on 
MAFLD [125]. A study by our group demonstrated that higher serum levels of irisin were 
correlated with decreased hepatic steatosis [125]. In addition, adipose tissue expression of 
FNDC5 and soluble plasma irisin levels were reported to correlate negatively with high blood 
glucose and triglycerides levels, visceral adiposity and extracellular lipid deposition [126]. 
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Figure 1.4: The influences of visceral ectopic fat accumulation, adipose tissue 
inflammation, type 2 diabetes, diet and intestinal dysbiosis to promote the development 
of progressive liver disease in MAFLD. Abbreviations: DAG, di-acylglycerol; HCC, 
hepatocellular carcinoma; LCFAs, long-chain fatty acids; PNPLA3, patatin-like 
phospholipase domain-containing 3) [42]. 
1.3.2.4 Gut Microbiota 
The liver derives the majority of its blood supply (approximately 70%) from the 
intestine through the portal circulation [127, 128]. This efficient connection between the liver 
and gastrointestinal tract is termed the gut-liver axis [129, 130]. The intestinal lining serves as 
an immunological barrier preventing the movement of antigens in the gut from entering the 
portal circulation [127]. Normally, a minor proportion of the gut microbiota reaches the liver, 
and should be eliminated by the hepatic innate immune system mediated principally by Kupffer 
cells [128]. In MAFLD, a high intake of a western diet and chronic low grade inflammation 
can cause a disturbance or imbalance in the composition of gut bacteria that is termed 
“dysbioisis” [42]. Under dysbiotic conditions, gut microbiota lose their local homeostasis and 
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interruption of the intestinal barrier follows [131]. There are multiple animal and human studies 
that have established an association between dysbiosis of gut microbiota and the development 
of MAFLD [132]. For instance, studies in animals have shown that high fat feeding of germ 
free mice decreases hepatic lipid compared to feeding conventional mice [133]. Furthermore, 
the supply of non-absorbable antibiotics to a MASH rat model reduced the risk of disease 
progressing to cirrhosis [134]. 
In humans, a cross sectional study by Raman et al. demonstrated an increase in 
Lactobacillus in obese patients with MAFLD compared to healthy controls [135]. Similarly, 
another study established that the Bacteroidetes/Firmicutes ratio was higher in MASH patients 
independent of diabetes risk factors or metformin usage compared to healthy controls [136]. 
Additionally, in a study by Zue et al. of 63 children (25 obese patients, 22 MASH patients, and 
16 healthy controls) it was noted that Proteobacteria /Enterobacteriaceae/Escherichia were 
equally represented in both control and obese microbiomes however they were higher in 
MASH [137]. Recently, our unit demonstrated a differential microbiota profile between 
subjects with lean (Erysipelotrichaceae/Clostridiales) and non-lean MAFLD 
(Ruminiclostridium/Streptococcus) that is likely involved in shaping the differential 
pathogenesis of these two subtypes [22]. 
 Functionally, dysbiosis has been implicated in altered energy homeostasis, increased 
inflammation, and choline and bile acid metabolism, which all contribute to the development 
and progression of MAFLD as shown in Figure 1.4 [42]. Moreover, dysbiosis prompts 
endotoxemia and inflammation of the gut wall and stimulation of Kupffer cells and hepatic 
stellate cells [127]. This is a consequence of activation of Toll-like receptors 9 and 4 as well as 
the TNF-α receptors [138, 139]. 
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1.3.2.5 Bile acids 
Bile acids are synthesized in the liver from cholesterol and are a component of bile 
[140]. Bile acids play a role in lipid emulsification and absorption of fat and fat-soluble 
vitamins [141]. They also act as signaling molecules by binding and mostly stimulation of 
nuclear hormone receptors such as the farnesoid X receptor, vitamin D receptor, and pregnane 
X receptor which are involved in maintaining bile acid, glucose and lipid homeostasis [142-
147]. Bile acids are modified by intestinal microbiota and reabsorbed in the terminal ileum by 
a process named enterohepatic circulation [169]. Through the process of bile acid modification, 
gut bacteria can change the size and composition of the bile acid pool with consequences on 
bile acid metabolism, synthesis, deconjugation and conversion of primary to secondary bile 
acid [170, 171]. 
In both rodents and humans with MAFLD/MASH, alterations in both total bile acid 
levels and composition have been noted [148].  Compared to healthy controls, total fasting and 
post-prandial serum bile acids are elevated in MASH patients [149]. In fact, it has been 
suggested that patients with steatohpatitis have a shift in bile acids composition to such an 
extent that there is an elevation in both taurine-and glycine-conjugated and elevated secondary 
bile acids [149, 150]. Similarly, in animal studies a modified bile acids composition was 
demonstrated in rats fed a high fat diet compared to normal chow [151]. Increased secondary 
bile acids can have harmful impacts and increase hepatic inflammation that eventually 
contributes to MASH progression and hepatocellular carcinoma development [152, 153]. The 
effect of gut microbiota on the development and progression of MAFLD may also be mediated 
in part through bile acids [154]. Given these effects, it is not surprising that bile acid analogues 
have been developed as a therapeutic target for MAFLD prevention and/or treatment [150, 155, 
156].  
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1.4 The Fibroblast Growth Factor family 
Fibroblast growth factors (FGFs) are a group of polypeptide growth factors that are 
found in virtually all organisms ranging from nematodes to humans [157]. The FGF proteins 
associated regulate diverse cell functions including cell development and differentiation, 
angiogenesis, repair and metabolic homeostasis [157, 158]. Both the human and mouse FGF 
gene families consist of twenty-two members [158]. In humans, the FGF gene family includes 
FGF1–FGF23. However FGF15 has not been identified in humans and is believed to be the 
orthologue of human FGF19 [158]. FGFs have been classified into seven subfamilies based on 
their sequence homology and mechanism of action [158]. Evolutionarily, the FGF gene 
subfamilies possibly evolved during the development of early vertebrates [159] to allow a 
contribution to numerous physiological and developmental processes [160]. 
The majority of FGFs known as canonical FGFs act in an autocrine and paracrine 
manner via binding to and activating cell surface tyrosine kinase FGF receptors (FGFR) 
through heparin sulphate glycosaminglycans which act as co-factors [161]. On the other hand, 
endocrine FGFs (eFGFs) or atypical FGF including FGF19, 21, and 23 differ from the 
canonical FGFs in some features as shown in Figure 1.5. The endocrine FGFs act as circulating 
hormones because they lack heparin-binding affinity allowing them to enter the systemic 
circulation. eFGFs depend on the presence of another membrane co-receptor, alpha Klotho or 
beta Klotho for signaling [162, 163].  
 The metabolic axes of the three eFGFs regulate a range of metabolic pathways resulting 
in tissue and organismal metabolic homeostasis of glucose, bile acids, energy, lipid and 
minerals [164-166]. Therefore, eFGFs have a particular potential to treat a variety of metabolic 
diseases and comorbidities [167]. On the basis of the aforementioned aspects, in the next 
section, I discuss the eFGF family with special emphasis on FGF21, the core of my thesis.    
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Figure 1. 5: Members of the FGF gene family and their evolutionary relationship 
Figure 1.5: Members of the FGF gene family and their evolutionary relationships [168]. 
1.4.1 Fibroblast Growth Factor 19 (FGF19) 
1.4.1.1 Sources/expression 
The primary source of FGF19 is the ileal enterocyte of the small intestine and 
enterocytes in the colon where its expression is induced by stimulation of the farnesoid X 
receptor via postprandial bile acids [162, 169]. This direct connection between FGF19 and bile 
acids renders FGF19 a postprandial hormone. Recently, both Schmidt et al. and Henkel et al. 
found that the FGF19 synthesis was also regulated by cholesterol and fat-soluble vitamins A 
and D [170, 171]. Moreover, the expression of FGF19 is modified by MAM (meprin-A5-
protein tyrosine phosphatase mu) and LDL receptor class A domain containing 1 (MALRD1 
or Diet1) protein transcriptionally and post-transcriptionally [172]. When FGF19 is discharged 
into the circulation, it acts on various metabolic organs with the liver, adipose tissue and brain 
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representing its primary targets as illustrated in Figure 1.6 [173]. Secreted FGF19 attaches to 
FGFR and β-Klotho co-receptor, facilitating different metabolic effects. 
Figure 1. 6: Synthesis and general actions of FGF19. 
Figure 1.6: Synthesis and principal actions of FGF19. Abbreviations:  FXR farnesoid X 
receptor, FGF19 fibroblast growth factor 19, FGFR fibroblast growth factor receptor, SHP 
nuclear small heterodimer partner, CYP7A1 cholesterol 7 α-hydroxylase, CREB cAMP-
response element-binding protein, PGC1α peroxisome proliferator-activated receptor γ 
coactivator 1-α, GSK, GS glycogen synthase kinase, WAT white adipose tissue, AgRP agouti-
related peptide, NPY neuropeptide Y [173]. 
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1.4.1.2 Function 
FGF19 has diverse functions  
 In the liver, FGF19 inhibits the enzyme cholesterol 7 α-hydroxylase (CYP7A1) and 
down regulates the synthesis of bile acids [174]. Furthermore, it regulates glucose homeostasis 
by preventing gluconeogenesis through the inhibition of cAMP-response element-binding 
protein (CREB)/peroxisome proliferator-activated receptor γ coactivator 1-α signalling [175].  
  In adipose tissue FGF19 improves insulin sensitivity and energy expenditure and as 
well decreases body weight and circulating levels of glucose [176-178]. In the brain FGF19 
acts on neurones to improve glycaemic homeostasis and decreasing food intake [179, 180].  
1.4.1.3 Pharmacological implications 
The discovery of the pharmacological activity of FGF19 preceded that of FGF21. In 
2018, the FGF19 analog NGM282 was examined in patients with MASH and was reported to 
significantly decrease liver fat content [181]. Additionally, NGM282 administration to mouse 
models and humans with cholestasis and primary biliary cholangitis demonstrated a significant 
reduction in bile acid levels and improved inflammatory injury and hepatic fibrosis [182-184]. 
However, compared to placebo controls, prominent side effects have been detected such as 
diarrhoea, abdominal pain, nausea and abdominal distension prompting temporary or 
permanent discontinuation of the drug [181].  
1.4.2 Fibroblast Growth Factor 23 (FGF23) 
1.4.2.1 Sources/expression 
FGF23 is mainly synthesized by osteoblasts in the bone in response to elevated 
phosphate, active vitamin D, parathyroid hormone and iron, and magnesium loss [185]. 
Moreover, its expression is detected in multiple organs such as the liver, spleen, thymus, 
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muscle, heart, and lung [162]. It controls calcium-phosphate homeostasis and the serum levels 
of vitamin D via the FGFR-α-klotho co-receptor complex [186-188]. 
1.4.2.2 Function 
In the kidney, FGF23 suppresses the sodium-dependent phosphate co-transporter 2A 
(NaPi-2a) expression thereby reducing reabsorption and increasing the secretion of phosphate 
[188]. Furthermore, FGF23 inhibits 1α-hydroxylase expression and activates 24α-hydroxylase, 
contributing to lowering serum 1,25 (OH)2 D3 levels [189].  
In the parathyroid gland which also expresses FGFR and α-klotho, FGF23 suppresses 
the production and secretion of parathyroid hormone as shown in Figure 1.7 [187, 190, 191]. 
Recently, FGF23 has been shown to have a further role in other metabolic processes for 
example energy homeostasis and insulin resistance as an eFGF family member [192, 193]. The 
role of FGF23 in MAFLD is not well defined. 
1.4.2.3 Pharmacological implications 
   FGF23 was exploited as a potential therapeutic target in preclinical models. Aono et 
al., reported that administration of neutralizing antibodies that target FGF23 in mice with 
hypophosphataemia normalized phosphate and vitamin D concentrations in their serum [194]. 
Another study demonstrated the role of peptide analogs of the FGF23 C terminus in fighting 
human hypophosphataemic diseases [195]. In chronic kidney disease, FGF23 levels have been 
elevated suggesting that other uses of the ligand might include the  treatment of renal disease 
[157]. 
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Figure 1. 7: Target organs of FGF23: the kidney and the parathyroid gland. 
Figure 1.7: Target organs of FGF23: the kidney and the parathyroid gland. Abbreviations: 
FGF23 fibroblast growth factor 23, PCT proximal convoluted tubules, NaPi-2a sodium-
dependent phosphate cotransporter 2A, Cyp27b1 1α-hydroxylase, Cyp24a1 24α-hydroxylase 
[173]. 
1.4.3 Fibroblast Growth Factor 21 (FGF21) 
1.4.3.1 Sources/expression 
FGF21 was first identified from the liver in 2000 by Tetsuya Nishimura and colleagues 
[196]. FGF21 has a hydrophobic amino terminus (~ 30 amino acids) which is a typical signal 
sequence and appears to be a secreted protein [196]. Mouse and human FGF21 have a high 
level of homology (75% at the amino acid level) [196]. 
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FGF21 is principally produced in the liver but is also expressed in other metabolic 
organs including the adipose tissue, gastrointestinal tract, and pancreas, and at lower levels in 
skeletal muscle, heart, kidneys, and testes [162, 196, 197]. FGF21 is also found in human 
cerebrospinal fluid [198], and can cross the blood–brain barrier in rats [199].  
Hepatic FGF21 expression is regulated by the peroxisome-proliferator-activated 
receptor-α (PPARα) pathway [200, 201] as well as by other nuclear receptors such as the 
cAMP-responsive element-binding protein H (CREB-H) which regulates triglyceride 
metabolism[202], the activating transcription factor 4 (ATF4) [203], and the glucocorticoid 
receptor [204]. Furthermore, circulating FGF21 concentrations exhibit a characteristic 
circadian rhythm (diurnal rhythm) in humans with a major nocturnal rise happening around 12 
AM and early morning leading to an increase in corticosterone secretion which subsequently 
promotes gluconeogenesis in liver [205]. Since FGF21 plays an important role in stress, levels 
are increased in different physiological and pathological conditions. For example, its 
expression is regulated by fasting (acutely in mice, chronically in humans), protein restriction 
(in mice and humans), ketogenic diets and obesity (in mice and humans), exercise (in mice and 
humans) as well as environmental stress, such as cold exposure [206-208].  
FGF21 acts as an endocrine hormone and has lower heparin-binding capacity and does 
not bind to the fibroblast growth factor receptor (FGFR) - heparin complex. Thus, a 
combination with transmembrane glycoproteins such α-klotho (KLA) or β-klotho (KLB) as co-
receptors is required for the signalling of FGFRs as shown in Figure 1.8 [209]. Notably, while 
FGFR1c is widely expressed, β-klotho expression is confined to metabolic tissues, including 
white adipose tissue, brown adipose tissue, the liver, the intestinal tract, the pancreas, and the 
cerebrum. Therefore, the activities of FGF21 are dictated by the nearness of this co-receptor 
and confined to these specific tissues [162, 163, 210]. In addition to the endocrine role of 
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FGF21, emerging evidence suggests that FGF21 also acts as an autocrine/paracrine factor 
acting on nearby target cells [162, 211]. 
 
Figure 1. 8: The mechanisms of paracrine and endocrine FGFs. The endocrine FGFs are secreted endocrine signals through 
the bloodstream, and the paracrine FGFs are locally secreted signals that act on nearby target cells by diffusion. 
Figure 1.8: The paracrine and endocrine actions of FGFs. The endocrine FGFs are 
secreted through the bloodstream, and the paracrine FGFs are locally secreted and act 
on nearby target cells by diffusion. Abbreviations: FGF, fibroblast growth factor; FGFR, 
fibroblast growth factor receptor [211]. 
1.4.3.2 Function 
 
FGF21 is a metabolic regulator with multiple beneficial effects on multiple targets as 
illustrated in Figure 1.10. In the liver, during fasting FGF21 plays a prominent role in hepatic 
metabolism via regulating fatty acid oxidation, ketogenesis, gluconeogenesis, and controlling 
sugar macronutrient preference, as well as via the suppression of lipogenesis (Figure 1.9) [200, 
212]. Furthermore, FGF21 has insulin sensitizing effects during the early stages of refeeding 
and overfeeding [213]. Thus, FGF21 acts as a defensive metabolic barrier for the harmful 
effects caused by metabolic disorders of the liver [214]. 
  28  
 
In adipose tissues, FGF21 prompt glucoses uptake by upregulating glucose transporter 
1 (GLUT1) [215, 216]. Furthermore, FGF21 in white adipocytes influences lipid storage by 
promoting mitochondrial oxidative capacity and PPARγ activity [217, 218]. Moreover, FGF21 
induces browning of white adipose tissue and stimulates uncoupling protein 1 expression, 
which results in activation of thermogenesis [219-221]. This then promotes energy expenditure 
and inhibits the development of overweight and obesity [222]. However, several studies have 
demonstrated that the metabolic impact of FGF21 on lipid and carbohydrates metabolism is 
not restricted to uncoupling protein 1-dependent effects [223, 224]. Notably, FGF21 also 
increases the synthesis of adiponectin an insulin-sensitizing adipokine, which could improve 
the inflammatory status and prevent lipotoxicity by repressing the NF-κB signaling pathway 
[225]. 
In the pancreas, high levels of FGF21 are suggested to act as an exocrine pancreatic 
secretagogue to stimulate pancreatic digestive enzyme secretion and pancreatic juice flow to 
the intestine, thereby relieving potential self-digestion caused proteostasis stress and protecting 
the pancreas from pancreatitis [226]. Moreover, FGF21 improves insulin sensitivity and lipid 
metabolism in obese or diabetic rodent models and has been proposed as a potential therapeutic 
agent for treating T2DM due to its effect on islet β-cells. FGF21 protects these cells from 
apoptosis and thus mediates its glucose-lowering function and lowers glucolipotoxicity [227-
231]. 
In skeletal muscles, FGF21 is considered as a myokine and plays a role in the regulation 
of muscle mass [232]. Physical exercise promotes the synthesis of FGF21 [233]. Two recent 
studies demonstrated that FGF21 treatment reduces the accumulation of lipid and improves 
insulin sensitivity via supressing the activation of stress-related kinases including the NF-κB 
signaling pathway [234, 235].  
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In the central nervous system (CNS), the nocturnal rise of FGF21 bears resemblance to 
that of cortisol which is secreted from the adrenal gland in circadian cycles via stimulating the 
hypothalamic-pituitary-adrenal axis [205]. Interestingly, FGF21 increases systemic 
glucocorticoid secretion which enhancing hepatic glucose production, suppresses physical 
activity and alters circadian behaviour. These effects are mediated through β-Klotho expression 
in the hypothalamus and the dorsal vagal complex of the hindbrain [236]. Hepatic FGF21 
signals to the brain reward pathway to suppress sugar and alcohol intake whereas it stimulates 
water drinking, neuronal gonadotropin-releasing hormone release, and pituitary function [237-
239]. 
In the heart, FGF21 has direct effects on decreasing the risk of cardiovascular diseases 
[240]. For instance both endogenous and exogenously FGF21 administered interacts with 
cardiomyocytes to protect them after myocardial ischemia/reperfusion damage [241]. 
Moreover, another target action of FGF21 is protection of the heart from hypertrophy in mice 
[242]. There is also evidence that it has protective effects against atherosclerosis. This is 
connected to its metabolic effects such as reductions in cholesterol by inhibiting sterol 
responsive element binding protein 2 expression in the liver and activation of the anti-
atherosclerotic molecule adiponectin in adipose tissue [243, 244].  
In the kidneys, FGF21 may play a role in the development of chronic kidney disease. 
Thus a recent study reported that higher plasma FGF21 levels were associated with lower 
estimated glomerular filtration rate and higher urinary albumin:creatinine ratio in participants 
who were free of clinically apparent cardiovascular disease [245]. Similarly, another study 
confirmed that higher serum FGF21 levels are found in patients with chronic kidney disease 
[246]. Interestingly that study found that in diabetic nephropathy, serum FGF21 levels correlate 
with the extent of albuminuria and the rate of loss of the glomerular filtration rate [246].  
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Figure 1. 9: Metabolic actions of FGF21. 
Figure 1.9: Metabolic actions of FGF21. Abbreviations: PPARα peroxisome proliferator 
activated receptor α, PPARγ peroxisome-proliferator-activated receptor γ, FGF21 fibroblast 
growth factor 21, FGFR fibroblast growth factor receptor, AT adipose tissue, WAT white 
adipose tissue, BAT brown adipose tissue, UCP1 uncoupling protein 1[173]. 
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Figure 1. 10: The relationship and the multiple between FGF21 with different organs and tissues. 
Figure 1.10: The relationship of FGF21 with different organs and tissues [211]. 
Abbreviations: FGF21, fibroblast growth factor 21; FGFR, fibroblast growth factor receptor; 
KLB, β-klotho; WAT, white adipose tissue; BAT, brown adipose tissue; UCP1, uncoupling 
protein-1; CVD, cardiovascular disease; MAFLD, non-alcoholic fatty liver disease; MASH, 
non-alcoholic steatohepatitis; TG, triglyceride; VLDL, very low density lipoprotein; GLUT-1, 
glucose transporter-1; NEFA, non-esterified fatty acids. 
1.4.3.3 Pharmacological implications 
Given the diverse favourable metabolic consequences of FGF21 signaling as shown in 
Figure 1.11 [271], it has been exploited as a therapeutic targets for multiple metabolic 
disorders particularly MAFLD. Strategies have included stimulating the expression and release 
of FGF21 or up-regulating the expression of FGF21 downstream effectors [247]. However, the 
short half-life of the native FGF21 protein (only 1 hour) limits its therapeutic effects.  
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Recently, several FGF21 analogue compounds with a prolonged half-life such as 
LY2405319 and PF05231023 have been developed to overcome this limitation. These 
compounds were investigated in mice and in human clinical trials. For instance, a study in 
ob/ob mice using subcutaneous administration of LY2405319 (half-life of around 3 h), have 
reduced plasma glucose and body weight [248]. This was followed by another study in MASH 
mouse models where LY2405319 (5 mg/kg) was injected IP for 3 weeks. That study reported 
a decrease in MASH progression by enhancing hepatic mitochondrial function [249]. 
  In humans, a randomized, placebo-controlled, double-blind trial  reported a beneficial 
impact of administration of 20 mg of LY2405319 daily for 28 days in reducing body weight, 
fasting insulin, and increasing serum adiponectin in patients with obesity and type 2 diabetes 
[250]. Similarly, a single intravenous dose of PF05231023 reduced LDL-Cholesterol plasma 
levels and elevated HDL-Cholesterol plasma levels in T2DM subjects [251].       
Furthermore, a recent phase II clinical trial with subcutaneous injection of Pegbelfermin 
(BMS-986036), a PEGylated human FGF21 (PEG-FGF21) analogue reduced hepatic fat 
content and biomarkers of fibrosis in patients with MASH (NCT02413372) [252]. Currently, 
two ongoing phase 2B randomized double-blind, placebo-controlled clinical trials are 
evaluating the safety and efficacy of BMS-986036 as listed on ClinicalTrials.gov. FALCON1 
(NCT03486899) has recruited 160 adults with MASH and stage 3 liver fibrosis is anticipated 
to be completed by September 27, 2021. FALCON2 (NCT03486912) has 100 adult participants 
with MASH and liver cirrhosis and is expected to be completed by April 5, 2021.  
Another approach for therapeutic targeting FGF21 is the b-klotho/FGFR1c receptor 
agonist NGM313 (retitled MK-3655168). This led to reductions in liver fat content in a Phase 
1b single dose study without a placebo arm in MAFLD patients (NCT03298464). 
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Additionally, several drugs that show beneficial effects on MAFLD have been 
demonstrated to do so in part through modulating the level of FGF21 [211]. For example, 
metformin treatment may reduce hepatic inflammation, steatosis, and fibrosis via upregulation 
of FGF21 expression and AMPK signaling [253]. Moreover, metformin activates the 
expression of FGF21 in both mouse models and human primary hepatocytes in vitro with 
beneficial effect to alleviate MAFLD only in mice models [254]. Nevertheless, metformin 
shows no effect in clinical trials of MAFLD patients [255]. On the other hand, rosiglitazone 
one of the PPARγ agonists has been shown to reverse hepatic steatosis, ameliorate insulin 
resistance, inhibit liver inflammation and ballooning necrosis in animals with MAFLD [256]. 
Additionally, in vitro rosiglitazone stimulates expression of FGF21 in murine and human 
adipocytes [257]. However, in FGF21-KO mice, rosiglitazone lost its beneficial effects on 
MAFLD, suggesting that FGF21 is required for the therapeutic effects of PPARγ agonists in 
patients [258]. Similar results were reported for fenofibrate. Treatment with fenofibrate 
demonstrated beneficial effects in MAFLD moue models via increasing the β-oxidation of 
FFA, diminishing hepatic insulin resistance, and supressing inflammatory mediator expression 
[233].A recent study showed that a peroxisome proliferator-activated receptor (PPAR) pan 
agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2methylpropanoic 
acid (MHY2013) upregulates FGF21 and adiponectin levels and prevents fatty liver formation 
and insulin resistance as well as inhibiting the expression of hepatic inflammatory mediators 
[259].  
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Figure 1. 11: The potential pharmacologic and non-pharmacologic agents affecting FGF21 in MAFLD. 
Figure 1.11: Potential pharmacologic and non-pharmacologic agents affecting FGF21 
expression in MAFLD. Some strategies reverse simple fatty liver and MASH potentially 
mediated by stimulating the expression and release of FGF21 or up-regulating the expression 
of FGF21 downstream effectors [247].  
1.5 Summary and research aims  
MAFLD is the commonest chronic liver diseases globally and in Australia [12, 260]. 
MAFLD is also a leading cause for end-stage liver disease, cancer and liver transplantation 
[26, 27]. The pathophysiology of MAFLD/MASH is complex and is likely the result of an 
interaction between environmental, genetic and epigenetic factors [23].  
Although MAFLD has high heritability, up to now, all recognized polymorphisms for 
MAFLD only explain 10–20% of the heritability [261]. Therefore, missing heritability exists. 
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Our unit has put forward the novel concept that leveraging the shared genetics between 
MAFLD and other metabolic diseases can help fill this missing heritability [262]. 
More recently it has been suggested that there is a genetic contribution to individual 
variability in macronutrient intake, and thus, the consequent related metabolic traits [263]. In 
this context, a recent study showed that the human FGF21 rs838133 variant is associated with 
increased sweet consumption and the latter is known to be linked to MAFLD development 
[264]. Thus this variant might be a novel additional and hitherto overlooked genetic variant 
affecting the severity of MAFLD. Moreover, the reported results of FGF21 in humans are still 
conflicting, with some reports suggesting that FGF21 levels are increased in MAFLD [265-
267] while other studies have failed to detect any effects [268]. This might relate to the methods 
of diagnosis, inadequate subgroup analyses, the inclusion of specific ethnic populations, and 
the small sample sizes in some of the studies. 
To address this gap in knowledge, in this thesis I investigated the role of the FGF21 
rs838133 variant and its serum levels in a well-defined cohort of patients with MAFLD (n = 
1209) with complementary mouse studies. My specific aims were to:  
Aim 1: Explore the role of the rs838133 polymorphism in the FGF21 gene in MAFLD. 
Aim 2: Characterise the histological and clinical effects of FGF21 and FGF23 in 
MAFLD.  
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Chapter 2: Materials and Methods 
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2.1 Human cohort 
The genetic study comprised a cohort of 1209 Caucasian patients with biopsy-proven 
MAFLD. Subjects were recruited from hepatology clinics at several Australian and European 
specialist liver centres: Westmead hospital, Sydney, Australia; Sir Charles Gairdner Hospital, 
Western Australia, Australia; Virgen del Rocío University Hospital, Sevilla, Spain; Hospital 
Clinico Universitario de Valladolid, Valladolid, Spain; University Hospital Santa Cristina, 
Madrid, Spain; Marqués de Valdecilla University Hospital, Santander, Spain; the Division of 
Gastroenterology, Turin, Italy and the Catholic University Hospital, Rome, Italy and 
University Clinic Leipzig, Leipzig, Germany. 
Ethics approval was obtained from the Human Research Ethics Committees of the 
Western Sydney Local Health District and the University of Sydney. All other sites had ethics 
approval from their respective ethics committees. Written informed consent for genetic testing 
was obtained from all participants. Subjects with evidence of secondary causes of steatosis or 
alternative diagnoses were excluded, including alcohol abuse (men, >30 g/day; women, > 20 
g/day), total parenteral nutrition, chronic viral hepatitis (hepatitis B and hepatitis C), 
autoimmune liver disease, hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s 
disease and drug-induced liver injury.  
2.2 Clinical and biochemical characterization 
Demographic and clinical data were obtained including age, gender, ethnicity, height 
and weight. Body mass index (BMI) was calculated as weight divided by the square of the 
height (kg/m2). Diabetes was defined as fasting blood glucose ≥ 7.0 mmol/L, previous 
diagnosis of diabetes or the use of antidiabetic drugs.  
At the time of liver biopsy, a fasting blood sample was obtained and routine biochemical tests 
were performed including ALT, AST, GGT and ALP, platelet, cholesterol, HDL-C, LDL and 
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triglycerides. The homeostasis model assessment (HOMA-IR) was calculated as: (fasting 
serum insulin [μU/mL] × fasting serum glucose [mmol/L])/22.5 [269, 270]. Additional blood 
samples were drawn and frozen at −80°C for future research. 
2.3 Genotyping  
Genotyping for FGF21 rs838133 was undertaken using the genotyping allelic 
discrimination method (Applied Biosystems, Foster City, CA, USA) with TaqMan GTXpress
™ Master Mix, catalogue number: 4401857 and TaqMan genotyping probe catalogue number: 
4351379. All genotyping was blinded to clinical variables.  
2.4 Liver histopathology 
            Liver biopsies were scored by an expert liver pathologist in each participating centre 
who was unaware of the clinical or genetic data. Histological scoring was based on the system 
proposed by Kleiner et al. [271]. Steatosis was graded from 1 to 3, lobular inflammation from 
0 to 3 and hepatocellular ballooning from 0 to 2. Fibrosis was staged from 0 to 4 with 4 
representing cirrhosis. The NAFLD activity score (NAS) was calculated to quantify disease 
activity[271]. The inter-observer agreement between pathologists was studied previously and 
was excellent for steatosis (K = 0.85) and good for fibrosis (K = 0.78) [272].  
 
2.5 High-throughput bile acid profiling 
Bile acids results were extracted from a recent report from our unit and the methods 
used have been previously described [22]. Briefly, bile acids were extracted from serum 
samples and 80 µL of acetonitrile containing internal standard (cholic2,2,4,4-d4acid; Quebec, 
Canada) was added to 20 µL of the serum sample. After centrifugation, the supernatant was 
evaporated to dryness and stored at −20°C until time of analysis. The dried bile acid residue 
was then reconstituted in mobile phase containing 50:50 water and acetonitrile and analyzed 
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on an Ultra-Performance Liquid Chromatography (UPLC; Shimadzu, Kyoto, Japan) system 
using an ACQUITY (Waters, Milford, MA) column in combination with a Q-TRAP 5500 Mass 
Spectrometer (AB SCIEX, Toronto, Canada) to quantify concentrations of 19 bile acids. The 
mass spectrometer was operated in negative ion mode. The calibration solution containing all 
19 analytes was prepared at a series of concentrations in pooled naive plasma depleted of bile 
acids using activated charcoal to generate the calibration curve. The detection limit for 
individual bile acids was 0.01- 0.05 μmol/L. The normal range for fasting total serum bile acid 
levels is 2-10 μmol/L [273]. 
2.6 Measurement of FGF19, FGF21 and FGF23 in human serum 
Concentrations of FGF19, FGF21 and FGF23 were quantified in serum of subjects 
according to the manufacturer’s instructions by using enzyme-linked immunosorbent assay 
(ELISA) kits (EHFGF19, Thermo Scientific), (DF2100, R&D Systems), and (DY2604-05, 
R&D Systems), respectively. 
2.7 MAFLD mice models  
2.7.1 High Sucrose Diet  
Male C57BL/6 mice were obtained from Animal Resources Centre (Perth, Australia) 
and used for diet studies commencing at week 8 and were exposed to a 120-hour light/dark 
cycle with free access to food and water. Mice were fed either a 33% sucrose diet (SF09-079; 
Specialty Feeds, Glen Forrest, Australia) starting at 8 weeks of age for 16 weeks or normal 
chow. At the time of harvest, mice were anesthetized with intraperitoneal ketamine (100 
mg/kg)/xylazine (10 mg/kg) injection after a 4-hour fasting period. Liver samples were 
harvested, rapidly snap frozen in liquid nitrogen, and stored at −80ºC. All procedures were 
approved by the Western Sydney Local Health District animal ethics committee and conducted 
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in accordance with animal experimentation guidelines of the National Health and Medical 
Research Council (NHMRC) of Australia. 
2.7.2 Methionine and Choline Deficient Diet (MCD) 
Male C57BL/6 mice were fed either the MCD diet model or control diet for 6 weeks 
by SMC Laboratories Inc. Technoport Tokyo. Liver samples were harvested, rapidly snap 
frozen in liquid nitrogen, and stored at −80ºC. 
2.7.3 Bile Duct Ligation (BDL) 
All mice included in the experiment were first weighed and examined for signs of 
physical or behavioural abnormalities. Animals showing any irregularities were excluded from 
the subsequent surgery. Mice were anaesthetized by inhalation with 4% isoflurane (2-chloro-
2-(difluoromethoxy)-1,1,1-trifluoro-ethane) in 100% oxygen with a flow rate of 4 L/min as 
inhalational anaesthesia. This anaesthesia not only reduces pain for the animal but also has the 
beneficial side-effect of acting as a relaxing agent on muscles, thereby simplifying intra-
abdominal operations. In a next step, the mice were shaved at the abdomen using an appropriate 
electric fur shaver. After the onset of anaesthesia, the content of the isoflurane was reduced to 
1.5–3.0% in 100% oxygen and the flow rate was adjusted to 1 L/min. During anaesthesia an 
ISOFLO vaporiser was used to allow isoflurane concentrations to be properly adjusted. 
2.7.3.1 Surgical procedures 
Prior to opening the abdominal wall, the abdomen was sterilized with a gauze swab 
soaked with an antiseptic solution. The abdomen was opened via a midline laparotomy with an 
incision of 2 cm in length using a sterile razor sharp surgical scissor from the xiphoid process 
to the region upstream of the urinary bladder. With this incision the cutis and fascia were 
separated thereby exposing the underlying peritoneum and the linea alba. The surrounding 
connective tissue that wrapped around the peritoneum was moved carefully using the end of 
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the scissors. The peritoneal cavity was then opened via a precise cut along the linea alba. To 
allow unhindered intervention at subsequent steps, a stainless steel Colibri retractor was 
inserted into the peritoneal cavity to spread the edges of the surgical incision. Subsequently, 
the edge of the liver was lifted with a wet cotton swab (using 0.9% NaCl solution), the gut was 
moved caudally, and the duodenum was pulled down to expose the portal vein, the hepatic 
artery and the common bile duct. 
2.7.3.2 Setting the ligatures 
As a first step, the common bile duct was separated carefully from the flanking portal 
vein and hepatic artery. For this purpose, micro-serrated forceps with tips that are 0.5 mm and 
curved was used. A 5-0 Mersilene suture was then carefully placed around the bile duct and 
tied with two surgical knots above the duodenum. Another 5-0 suture was then tied in the same 
manner immediately near the hilum of the liver. When all knots were fixed, superfluous sutures 
were removed and the peritoneal cavity was rinsed with a 0.9% NaCl solution. Thereafter, the 
sternum was lowered and brought into a normal position. The retractor was removed from the 
cavity and all organs were placed into a physiological position by gently shaking the abdomen. 
The peritoneum and the cutis plus fascia were then closed layer by layer and with separate 6-0 
Mersilk sutures. 
2.7.3.3 Postoperative animal treatment 
After surgery, animals were allowed to recover and carefully observed until they 
recovered fully and behaved normally. To detect potential complications as early as possible, 
animals that underwent BDL or sham surgery were monitored at regular intervals (twice daily).  
2.8 RNA extraction and first-strand cDNA synthesis 
Total RNA was extracted from tissue lysate using the Qiagen RNeasy Kit according to 
the manufacturer‘s instructions. In brief, 10 mg of liver tissue was lysed in 350 μl of RNeasy 
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lysis buffer and transferred to a new RNase-free tube. Next, 350 μl of 70% ethanol was added 
to each cell lysate and mixed thoroughly. 700 μl of sample solution was applied to an RNeasy 
spin column in a collection tube and centrifuged for 30 seconds at 10,000 RPM. The flow-
through was discarded and 700 μl wash buffer RW1 was added to each spin column and 
centrifuged for 30 seconds at 10,000 RPM. After transferring the spin column to a clean tube, 
500 μl of second wash buffer RPE was applied to each column and the tubes centrifuged as per 
the process described above. This step was repeated. RNA was then eluted from the spin 
column with 50 μl of RNase-free water and centrifuged for one minute at 10,000 RPM into a 
clean, RNase-free tube. Eluted RNA was quantified using a NanoDrop ND1000 
spectrophotometer and stored at -80 °C for subsequent experiments. 
cDNA was reverse transcribed from total RNA using qScript® cDNA SuperMix cat# 
95048 (Quanta Biosciences, Gaithersburg, MD, USA) according to the manufacturer’s 
instructions. In brief, 1-10 μg RNA and 4μl qScript cDNA SuperMix were added to a sterile 
RNase-free microcentrifuge tube and the volume completed to 20 μl by RNase/DNase-free 
water. The mixture was incubated for 5 minutes at 25°C, then 30 minutes at 42°C, 5 minutes 
at 85°C and finally held at 4°C using Mastercycler gradient 5331 (Eppendorf AG, Hamburg, 
Germany). The synthesized cDNA was stored at -20 °C for further experiments. 
2.9 Real-time quantitative PCR 
Real-time PCR was performed in duplicate on Applied Biosystems, Foster City, CA, 
USA. Using TaqMan Fam labelled, murine FGF21 gene expression probe (Mm00840165_g1, 
Catalog number: 4331182) and TaqMan™ Fast Advanced Master Mix (Catalog number:  
4444556).  In each PCR tube, 10 μl of Master Mix was added to 1 μl of the probe, 6 μl of 
DNAse/RNAse free water and 3 μl of the diluted cDNA template (dilution of cDNA was 1:50 
of dH2O). The mRNA levels in murine liver tissue were normalised to the expression of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using TaqMan Fam labelled gene 
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expression GAPDH probe (Mm99999915_g1, catalogue number: 4331182). Expression was 
measured using CT values normalized to that of GAPDH (ΔCT = CT (GAPDH) - CT (target) 
and then expressed as 2-ΔCT.  
2.10 Statistical analysis 
Data were analysed using SPSS version 24.0 (IBM, Armonk, NY). Normally 
distributed data were expressed as mean ± standard error of the mean (SEM). The Student’s t-
test or non-parametric, i.e. Wilcoxon-Mann-Whitney or U-test tests were used to obtain 
significance between two means of continuous variables. Correlations among the study 
variables were tested by spearman’s correlation coefficient (e.g FGF21 by blood glucose or 
GGT levels). Univariable analysis of variance (ANOVA) was used to examine factors 
associated with increasing total secondary bile acid levels as a continuous variable. Statistical 
significance was considered as P < 0.05. 
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Chapter 3: Exploring the role of the 
rs838133 polymorphism in the 
FGF21 gene in MAFLD 
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3.1 Introduction 
Globally, MAFLD is the commonest cause of chronic liver disease and affects about a 
third of global population [12]. The progressive form of this disease is known as metabolic 
associated steatohepatitis (MASH) and is characterized by inflammation, hepatocyte necrosis, 
and in many cases, fibrosis [274]. MAFLD is a systemic disease that not only increases the risk 
of hepatic complications but also increases the frequency of extrahepatic complications such 
as cardiovascular disease, type 2 diabetes, and cancer [12]. The pathogenesis of the disease is 
the ultimate outcome of a complex interaction between genes and environmental factors [23].  
MAFLD has high heritability based on a twin study where the estimated heritability of 
liver fibrosis assessed by magnetic resonance electrography and steatosis quantified by MRI-
determined proton-density-fat-fraction was approximately 50% for both [47]. To date, all 
identified polymorphisms for MAFLD explain only 10–20% of the diseases’ heritability [261]. 
Thus, other common variants with modest size effect or rare variants are likely contributing to 
the heritability of MAFLD, but are yet to be explored. In this regard, a novel concept out 
forward by our unit suggests that leveraging shared genetics between MAFLD and other 
metabolic disease can inform the systems biology of MAFLD and help fill the missing 
heritability [262]. 
Different dietary constituents affect the development and progression of MAFLD [88, 
275-277]. Carbohydrates, fats and proteins are the principal macronutrients associated with 
MAFLD and MASH development, independent of weight and energy intake [278]. In 
particular, there is currently strong evidence from human and animal studies suggesting that 
sugar is a major risk factor of MAFLD. Semiane et al. (2017) reported that a high carbohydrate 
diet (75% as dried dates and 25% as barley) prompted MASH development [275]. Furthermore, 
consumption of a low carbohydrate diet results in hepatic triglycerides reduction in subjects 
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with MAFLD [279, 280]. Similarly, fructose ingestion has been implicated in the development 
of MAFLD in both human and animal studies [281, 282].   
Very recently, it has been recognised that there is a genetic basis to individual 
variability in macronutrient intake. For example, a recent multi-trait macronutrient genome-
wide association study (GWAS) from the UK Biobank identified 12 novel loci as determinants 
of macronutrient dietary intake and demonstrated overlap with the risk loci for type 2 diabetes 
and cardiovascular disease [263]. Thus, this finding pinpoints the overlap between the genetic 
architecture of dietary intake and the consequent related traits. In this context, a recent study 
suggested that the FGF21 rs838133 A allele is associated with pleiotropic effects including a 
higher percentage of sugar intake, blood pressure and waist-to-hip ratio, notwithstanding a 
relationship with a lower total body fat percentage [264]. These findings are consistent with 
data from animal studies demonstrating that FGF21 suppresses sweet preference by acting on 
the hypothalamus [237, 238]. However, the role of this variant in MAFLD and the functional 
mechanisms are obscure. 
 In this work, I explore whether the FGF21 rs838133 variant can be a novel risk variant 
for MAFLD and try to elucidate the functional mechanisms for this variant.  
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3.2 Results 
3.2.1 Patient characteristics and genotype distribution 
The genotype distribution of FGF21 rs838133 was in Hardy-Weinberg equilibrium (p 
= 0.1) in a large well characterized cohort of Caucasian patients (n =1209); their characteristics 
are presented in Table 3.1 and their genotype distribution is presented in Table 3.2. The minor 
allele frequency (MAF) of FGF21 rs838133 was 43% similar to that observed in a healthy 
European population from the 1000 genome project (http://browser.1000genomes.org).  
Table 3. 1: Demographic, anthropometric and clinical characteristics of the patient 
cohort with MAFLD 
 
Data are presented as median and range. HOMA-IR, Homeostatic Model Assessment of Insulin 
Resistance. BMI; body mass index. 
 
Variables MAFLD cohort (n = 1209) 
Age (yrs) 48 (38-58) 
Male (%)  640 (52.9) 
BMI (Kg/m2) 30.8 (27.6-36.6) 
ALT (IU/L) 53 (32-88) 
AST (IU/L) 35 (24-51) 
GGT (IU/L) 54 (31-105) 
Platelet (x109/L) 241 (198-287) 
Diabetics (%) 297 (24.6) 
Cholesterol (mmol/L) 4.93 (4.22-5.7) 
Triglycerides (mmol/L) 1.48 (1.05-2.19) 
HDL-C (mmol/L) 1.2 (1-1.5) 
LDL-C (mmol/L) 2.9 (2.3-3.6) 
Blood glucose (mmol/L) 5.4 (4.9-6.38) 
HOMA-IR 3.2 (2.007-5.18) 
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Table 3.2: Distribution of FGF21 rs838133 genotype and Hardy-Weinberg equilibrium.  
FGF21 rs838133 MAFLD 
(Caucasian population) (n =1209)  
AA 235 
AG 556 
GG 418 
A allele 43% 
G allele 57% 
Table 3. 2. Distribution of FGF21 rs838133 genotype and Hardy-Weinberg equilibrium. 
p = 0.1. P values were calculated by chi square test, p > 0.05 indicates no deviation from Hardy-
Weinberg equilibrium. 
3.2.2 FGF21 rs838133 and hepatic steatosis 
To explore the association of rs838133 with steatosis, I undertook analysis in the 1209 
patients from the entire cohort with MAFLD. No significant difference in the distribution of 
the FGF21 rs838133 genotype according steatosis grade was observed (p = 0.2) (Figure 3.1). 
 
Figure 3. 1: FGF21 rs838133 variant showed no effect on steatosis. 
Figure 3.1: The FGF21 rs838133 variant showed no effect on steatosis. There was no 
association observed between rs838133 and the degree of steatosis (p = 0.2). 
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3.2.3 Association of FGF21 rs838133 genotype with liver injury 
We next assessed the association between the FGF21 rs838133 variant and liver 
damage (hepatic inflammation and fibrosis). The distribution of rs838133 genotype according 
to histological features is depicted in Figure 3.2 to Figure 3.5. 
First, in univariate analysis rs838133 (A) allele was associated with lobular 
inflammation (p = 0.003), using an additive model (Figure 3.2A). Notably, the effect was more 
profound when the cohort was dichotomized into absent (0) versus any inflammation (A1–A3) 
(p = 0.0001) (Figure 3.2B). The effect remained significant when we adopted a dominant 
model and compared the presence of any inflammation (Odds ratio (OR): 1.77; 95% confidence 
interval (CI): 1.34 - 2.33, p = 0.0001) (Figure 3.2C), and after adjusting for age, gender, body 
mass index (BMI), type 2 diabetes mellitus (OR: 1.67, 95% CI: 1.29 - 2.16,  p = 0.0001).The 
(A) allele was also associated with severe inflammation (A2-A3) (OR: 1.32; 95% CI: 1.01 - 
1.71, p = 0.04).   
Similarly, there was a trend for rs838133 AA genotype association with severity of 
ballooning, though this was not significant (p = 0.069) (Figure 3.3).  
I next examined the association of the rs838133 genotype with fibrosis. No association 
was observed with either fibrosis stage or with significant fibrosis (p = 0.9) (Figure 3.4). 
Lastly, I examined the association of the rs838133 genotype with the NAFLD Activity 
score (NAS) which was calculated to quantify disease activity and is the arithmetic sum of 
steatosis (0–3), ballooning (0–2) and lobular inflammation (0–3) [271]. Consistently, an 
activity score of > 3 were significantly higher in subjects carrying the (A) allele, as compared 
to those with the (G) allele (p = 0.006), as shown in Figure 3.5.  
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Figure 3. 2: FGF21 rs838133 significantly inflammation. 
Figure 3.2: FGF21 rs838133 significantly associated with  lobular inflammation. In a large 
cohort of MAFLD patients (n = 1209), the minor (A) allele was associated with a higher degree 
of lobular inflammation (p = 0.003) (A) and the effect was more profound when the cohort was 
dichotomized into absent (0) versus any inflammation (A1–A3) (p = 0.0001) (B) or when a 
dominant model for the minor allele was adopted (p = 0.0001) (C). 
A B 
C 
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Figure 3. 3: Genetic variant of FGF21 showed no Effect on Ballooning. 
Figure 3.3: FGF21 rs838133 showed no significant association with ballooning. No 
significant difference was noted in ballooning according to FGF21 rs838133 status (p = 0.069).  
 
Figure 3. 4: Genetic variant of FGF21 showed no effect on Fibrosis. 
Figure 3.4: FGF21 rs838133 showed no association with fibrosis stage. No difference was 
noted in liver fibrosis according to FGF21 rs838133 (p = 0.9).  
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Figure 3. 5: FGF21 rs838133 association with activity score (NAS). 
Figure 3.5: FGF21 rs838133 association with the NAFLD activity score (NAS). The minor 
(A) allele was associated with the NAFLD activity score (p = 0.006). 
3.2.4 Exploring the functional mechanisms of the FGF21 rs838133 variant  
3.2.4.1 FGF21 rs838133 association with hepatic FGF21 expression 
Having established that FGF21 rs838133 strongly impacts hepatic inflammation, I 
turned my focus next to investigate the functional mechanisms of the effect. rs838133 is a 
synonymous variant so it is not predicted to affect the protein amino acid sequence directly. 
  As a first step, I tested if the rs838133 SNP controls hepatic FGF21 expression. To do 
this I performed allele-specific expression (ASE) analysis, using Real time PCR of cDNA from 
13 human liver samples from rs838133 heterozygous individuals. ASE analysis is a powerful 
method to study the effects of genetic variants on gene regulation and can be used as a marker 
to identify candidate genes with differential expression and even subtle differences in transcript 
levels [283]. As demonstrated in Figure 3.6, I did not find any significant allelic differences in 
gene expression between the minor (A) and the major allele (G) (p = 0.3). To further confirm 
these findings, I queried publically available databases to explore whether FGF21 rs838133 
regulates transcript expression as recent data indicates that expression quantitative trait loci 
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(eQTLs) may affect gene expression in a tissue- and cell-dependent manner [284]. However, 
no FGF21 eQTL for the rs838133 SNP was demonstrated. I then measured FGF21 by an 
enzyme-linked immunosorbent assay (ELISA) in serum samples from a sub-cohort of MAFLD 
patients (n = 109). However, there was a nonsignificant trend for increased serum levels of 
FGF21 in patients carrying rs838133 AA genotype (p = 0.3). Further increasing of sample size 
would be required to clarify this aspect (Figure 3.7). In total, rs838133 had no effect on hepatic 
FGF21 mRNA expression, but probably could have an impact on FGF21 serum levels. 
 
Figure 3. 6: FGF21 rs838133 has no effect on hepatic allele specific expression (ASE). 
Figure 3.6: FGF21 rs838133 has no effect on hepatic allele specific expression (ASE). 
Allele-specific ratio quantified by real-time PCR in subjects heterozygous for rs838133. No 
difference in the expression of the minor (A) (n = 13) compared with major allele (G) (n = 13) 
(p = 0.3) was observed. Statistical differences between the groups was assessed by the unpaired 
t test, and the data are presented as mean ± SEM.   
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Figure 3. 7: Association between FGF21 rs838133 genotype and serum levels in MAFLD patients (n = 109). 
Figure 3.7: Association between FGF21 rs838133 genotype and serum levels of FGF 21 
in MAFLD patients (n=109). There is a nonsignificant trend toward increased expression of 
FGF21 serum levels in patients harbouring the FGF21 rs838133 AA genotype (353 ± 55.47, n 
= 22) compared to AG (258.4 ± 35.84, n = 32) and GG (307.2 ± 36.44, n = 55) genotypes, (p 
= 0.3). Statistical differences between groups were assessed by one-way ANOVA, multiple 
comparisons was by Bonferroni correction, and the data presented are mean ± SEM. 
3.2.4.2 FGF21 rs838133 is not in high linkage disequilibrium with other variants in the 
European population 
Next, I thought to identify if there are any potential other candidate functional variants in the 
FGF21 gene region which can explain the observed genetic association. To do this I searched 
for variants in high linkage disequilibrium with rs838133 by analysis of available human 
genome sequence data (1000 genomes.org) queried by Haploreg [285]. No SNPs with high LD 
with rs838133 could be identified (Figure 3.8).  
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Figure 3. 8: The SNP has no strong linkage disequilibrium (LD) with any other potentially functional SNP. 
Figure 3.8: The rs838133 SNP was not in strong linkage disequilibrium (LD) with any 
other potentially functional SNPs. 
3.2.4.2 Exploring other potential mechanisms for the functional effects of FGF21 
rs838133 
Recent data have challenged the notion that synonymous substitutions have negligible 
effects on phenotype [286], with three mechanisms proposed for mediating the functional effect 
These include alternate splicing (protein or small RNA binding), mRNA structure and stability, 
or through the kinetics of translation (Figure 3.9). These I explored. 
 
3.2.4.3 SNP does not affect splicing  
I used an exonic splicing enhancer finder (http://exon.cshl.edu/ESE/), a web-based resource 
that facilitates rapid analysis of exon sequences that directs or enhances accurate splicing of 
heterogeneous nuclear RNA or pre-mRNA into messenger RNA (mRNA)[287]. In this 
analysis, the FGF21 rs838133 SNP was not predicted to affect splicing. 
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Figure 3. 9: The rs838133 SNP does not affect splicing. 
Figure 3.9: The rs838133 SNP does not affect splicing using an exonic splicing enhancer 
finder (http://exon.cshl.edu/ESE/).  
3.2.4.4 The FGF21 rs838133 SNP alters mRNA structure 
The RNA fold online server was used to deduce secondary structures of the mRNA and 
the minimum folding energy of FGF21-A and FGF21-G (Vienna RNA package, version 2.0.0, 
with option ‘-p’) [288]. Interestingly, as per Figure 3.10, the rs838133 A and G alleles have 
substantially different mRNA structures suggesting that the underlying mechanism of the 
genetic effect of this variant could be through mRNA structure. 
  57  
 
Figure 3. 10: Bioinformatics analysis for prediction of rs838133 impact on RNA folding structures.
 
Figure 3.10: Bioinformatics analysis for prediction of rs838133 impact on RNA folding 
structure. By using the RNA fold browser, the structures corresponding to rs838133 A or G 
allele are presented and demonstrate different mRNA structures.  
3.3 Discussion 
In this chapter, using a well characterized large cohort comprising 1209 Caucasian 
patients with MAFLD, FGF21 rs838133 was identified as a novel risk variant for hepatic 
lobular inflammation in MAFLD, but not for steatosis. The data I present further suggests that 
the mechanism of action is likely via changing of the FGF21 mRNA structure.   
FGF21 rs838133 (A) allele was robustly associated with hepatic inflammation. The 
effect was also observed when different analyses were considered such as adopting a dominant 
model, considering dichotomization of the cohort according to the presence and severity of 
inflammation or after adjusting for multiple potential confounding including age, gender, BMI 
and diabetes. Consistently, there is strong evidence from animal studies suggesting that FGF21 
has anti-inflammatory effects. For example, Fgf21 overproduction in mice by adeno-associated 
viral vector-mediated gene therapy hinders macrophage infiltration in the liver [289]. In 
addition, recombinant human FGF21 and long-acting FGF21 administration attenuates hepatic 
Allele G Allele A 
  58  
 
and circulating pro-inflammatory cytokine levels [290, 291]. Functionally, multiple 
mechanisms have been suggested for these anti-inflammatory effects of FGF21. For example, 
FGF21 possess anti-inflammatory effect on macrophages by hindering nuclear factor kB (NF-
kB) activation and activating the nuclear factor erythroid 2-related factor 2 (Nrf2) signalling 
pathway which has anti-inflammatory activity [292]. Furthermore, FGF21 can protect 
hepatocytes from inflammatory insults by protecting them from endoplasmic reticulum (ER) 
stress and attenuating the NF-κB and c-Jun N-terminal kinase (JNK) pathways [293, 294].  
No association between FGF21 rs838133 genotype and hepatic steatosis was found. 
According to my data, genotypic variation at rs3480 has a modest effect size on inflammation. 
However my data did not demonstrate an effect on steatosis, but it does not exclude the 
possibility of effects on steatosis in larger cohorts powered to detect such effects. This is 
relevant as some animal studies showed that FGF21 reduces hepatic steatosis and downregulate 
genes involved in lipid synthesis such as (Scd1, Pklr, and Gck) [295, 296]. However, another 
possibility is that this variant disentangles effects on steatosis and liver injury.  
Identifying the functional mechanisms of genetic variants relevant to human diseases 
is emerging as a major challenge in the post-GWAS era [297]. In this context, to provide 
insights on the functional mechanism of the rs838133 SNP. I elucidated that the rs838133 SNP 
has no effect on hepatic FGF21 allele specific expression or on its serum levels. Consistently,  
no FGF21 expression quantitative trait loci (eQTL) was found [298]. The robust genetic 
association of rs838133 with hepatic inflammation, the reported association of this variant with 
other metabolic traits and since no other potentially functional variants in high linkage 
disequilibrium with rs838133 could be identified i [285], it suggests that  rs838133 is likely the 
functional variant.  
On further investigation I demonstrated that rs838133 SNP is predicted to drastically 
alter mRNA structure. This suggests that the rs838133 SNP may affect the stability of FGF21 
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mRNA thereby reducing its translational efficiency as well as changing the functional mRNA 
half-life [299]. This very interesting finding will need to be further explored by examining 
RNA structural analysis by selective 2'-hydroxyl acylation, analyzed by primer extension 
(SHAPE). This takes advantage of the reactivity of small electrophilic chemical probes that 
react with the 2'-hydroxyl group to assess RNA structure at nucleotide resolution. When 
coupled with mutational profiling (MaP) in which modified nucleotides are detected as internal 
miscoding during reverse transcription and then read out by massively parallel sequencing, 
SHAPE yields quantitative per-nucleotide measurements of RNA structure [300]. This will be 
a future directions. 
In conclusion in this chapter I provide evidence for a role for the FGF21 rs83813 SNP 
as a novel risk variant for hepatic inflammation in MAFLD. This could help in efforts to fill 
the missing heritability of MAFLD. The functional mechanisms of the FGF21 rs838133 SNP 
is not via changing gene expression level or splicing, but is possibly via changes to mRNA 
folding and subsequently stability. This will need to be further investigated.   
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Chapter 4: Characterisation of the 
histological and clinical associations 
of FGF21 and FGF23 
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4.1 Introduction 
Metabolic associated fatty liver disease (MAFLD) (formerly known as NAFLD) [301] 
is one of the most common and serious chronic liver diseases [302]. The spectrum of disease 
extends from lipid accumulation (steatosis) to its severe inflammatory form, metabolic 
associated steatohepatitis (MASH) that increases the risk of cirrhosis and hepatocellular 
carcinoma, liver transplantation and death as well as extra-hepatic complications such as 
diabetes, cardiovascular diseases, chronic kindy disease, osteoporosis and some types of non-
liver cancer [12, 274].     
 The pathogenesis of the disease is complex and the multiple hit hypothesis has been 
suggested [129, 303]. While MAFLD has a heritable disease as recently reviewed [262], 
numerous environmental interacting factors are implicated in its pathogenesis [304, 305]. In 
addition, our unit and others have characterised a role for adipocytokines such as adiponectin 
and leptin [306, 307] and myokines such as irisin in MAFLD development and progression 
[125]. 
 Recently, a role for fibroblast growth factors (FGF) family members in obesity and 
metabolic diseases is emerging [308]. FGFs orchestrate a wide range of biological functions 
including the regulation of cell proliferation and differentiation, inflammation and wound 
healing [159]. In particular, FGF21 is a metabolically active hormone mainly derived from the 
liver, suggesting that it could play a pivotal role in the pathophysiology of MAFLD [216, 309]. 
Data from animal models suggests that FGF21 can increase energy expenditure, stimulate 
insulin sensitivity, induce weight loss and can acts as a negative regulator of bile acid synthesis 
[310], while the correlation between bile acids and FGF21 in humans is unknown. The known 
physiological effects of FGF21 are the basis for clinical trials investigating its role as a 
therapeutic target for MAFLD [311]. 
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 In contrast to the obvious beneficial metabolic effects of FGF21 in animal studies, 
results of FGF21 in humans remain conflicting. Although early reports suggested that FGF21 
levels are elevated in patients with MAFLD compared to healthy controls [265-267], other 
studies failed to discern this finding [268]. Similarly, contradicting data was reported regarding 
the correlation of FGF21 level to disease severity [312]. While, both Dushay et al. and Li et al. 
reported that FGF21 mRNA hepatic expression was elevated in patients with steatosis [265, 
313], Barb et al. found no association between FGF21 serum levels and the degree of steatosis 
[268]. Similarly, for correlation with MASH, while some reports found an increase in FGF21 
serum levels in MASH compared to subjects with steatosis or no MAFLD [268, 314, 315], 
other studies find the opposite or no difference at all [316-318]. I reasoned that this controversy 
in results might be attributed to difference in methods of diagnosis of MAFLD between these 
studies, as most were not biopsy proven with MAFLD diagnosed by ultrasonography [267, 
312, 313]. In addition, results of studies from MAFLD subpopulations such as overweight [266, 
268], diabetic or bariatric surgery [268, 318] groups might not be applicable to the general 
MAFLD population. Moreover, the vast majority of these studies were conducted in Asian 
populations [267, 312-315] while the role of FGF21 in Caucasian are less well characterised. 
Finally, the sample sizes of some of the previous studies have been small [265-267]. 
 Hence, in this chapter I sought to characterise the role of FGF21 in MAFLD utilising a 
well characterized cohort of patients with biopsy-proven MAFLD and matched healthy 
controls (n = 114 and 44, respectively). In addition, I explored FGF21 correlation with clinical, 
metabolic, histological features and bile acid levels. Finally I investigated the role of the other 
members of the eFGF family (FGF19, FGF23) in MAFLD. Hepatic FGF21 expression in 
different MAFLD animal models was also assessed. 
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4.2 Results 
4.2.1 FGF21 serum levels were increased in metabolic-associated fatty liver disease 
(MAFLD). 
Data on FGF21 levels in MAFLD remain conflicting. Therefore, we assessed the serum 
levels of FGF21 by ELISA in biopsy-proven MAFLD patients (n = 114) and healthy controls 
(n = 44). As illustrated in Figure 4.1, elevations in FGF21 serum levels were detected in 
patients with MAFLD compared to healthy controls (p < 0.05).  
 
Figure 4. 1: FGF21 serum levels in patients with MAFLD and healthy controls. 
Figure 4.1: FGF21 serum levels in patients with MAFLD and healthy controls. The FGF21 
serum level was significantly increased in MAFLD patients (301.3 ± 22.98, n = 114) compared 
to healthy controls (211.6 ± 30.46, n = 44) (p = 0.03). Statistical differences between the two 
groups were assessed by the unpaired t test (* p < 0.05) and the data presented are mean ± 
SEM. 
4.2.2 FGF21 serum levels were upregulated in MASH, but not with steatosis 
In the previous chapter my genetic results suggested that the A allele of the FGF21 
variant rs838133 was significantly associated with hepatic inflammation in MAFLD, but not 
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with hepatic steatosis. Thus, I analysed the serum levels of FGF21 in MAFLD patients, 
comparing those with simple steatosis to MASH.  
While there was no significant difference between healthy control and simple steatosis 
patients (p = 0.9), an elevation in FGF21 serum levels was detected in patients with MASH 
compared to healthy control and those with simple steatosis (p = 0.002, p = 0.009, respectively). 
These results are in line with my genetic findings suggesting that FGF21 is implicated in 
MASH, likely due to hepatic FGF21 resistance (Figure 4.2).  
 
Figure 4. 2: The FGF21 serum levels in patients with MASH, simple steatosis and healthy control. 
Figure 4.2: FGF21 serum levels in patients with MASH, simple steatosis and healthy 
controls. The FGF21 serum level was significantly increased in MASH patients (373.6 ± 40.5, 
n = 44) compared to healthy controls (211 ± 30.46, n = 44) (p = 0.002) and those with simple 
steatosis (218.4 ± 30.08, n = 31) (p = 0.009). No significant change was detected in FGF21 
serum levels between healthy controls and simple steatosis patients (p = 0.9). Statistical 
differences between groups were assessed by one-way ANOVA (** p < 0.01), multiple 
comparisons was by Bonferroni correction and the data presented are mean ± SEM.  
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4.2.3 FGF21 serum levels and NAFLD activity score (NAS Score) 
Total NAS score sums the scores for steatosis, lobular inflammation, and ballooning, 
and ranges from 0-8. The NASH score is considered as valuable tool to quantify variations in 
MAFLD activity in therapeutic trials [319]. Hence, I further compared FGF21 serum levels in 
patients with a low NAS score (0-2) and those with a NAS score between 3 and 7. As depicted 
in Figure 4.3, FGF21 was increased in those with a higher NAS score (p < 0.05).  
 
Figure 4. 3: The FGF21 serum levels changes in NAS Score. 
Figure 4.3: FGF21 serum levels with changes in the NAS Score. The FGF21 serum level 
was significantly raised in patients with a NAS score (3-7) (377.6 ± 32.17, n = 64) compared 
to that in patients with a NAS score (0-2) (262.4 ± 30.11, n = 53) (p = 0.01). Statistical 
differences between the groups were measured by the unpaired t test (* p < 0.05) and the data 
presented are mean ± SEM. 
4.2.4 FGF21 serum level changes during fibrosis 
Fibrosis is the major determinant of all MAFLD related complications [30]. Thus, I 
evaluated the relationship between serum levels of FGF21 and fibrosis stage. FGF21 serum 
levels were significantly elevated in patients with any fibrosis compared to patients with no 
fibrosis (p < 0.05) (Figure 4.4). 
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Figure 4. 4: The FGF21 serum levels according to MAFLD related fibrosis. 
Figure 4.4: FGF21 serum levels according to MAFLD related fibrosis stage. The FGF21 
serum level was significantly increased in patients with any fibrosis (F1-F4) (319.9 ± 27.92, n 
= 67) compared to those with no fibrosis (F0) (232.4 ± 29.61, n = 40) (p = 0.04). Statistical 
differences between the groups were evaluated by the unpaired t test (* p < 0.05) and the data 
shown are mean ± SEM. 
4.2.5 FGF21 serum levels in lean compared to non-lean MAFLD patient 
Our unit recently investigated serum FGF19 levels in lean and non-lean MAFLD 
patients. This study established that patients with lean MAFLD had significantly elevated 
serum FGF19 concentrations compared to non-lean MAFLD patients, suggesting differences 
in metabolic adaptation in lean MAFLD patients [22]. Therefore, I explored if there were 
similar differences in FGF21 serum levels between lean and non-lean MAFLD patients. As, 
per Figure 4.5, in contrast to FGF19, no significant differences in serum FGF21 concentrations 
were noted between lean MAFLD compared to non-lean MAFLD (p = 0.4). 
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Figure 4. 5: FGF21 serum levels in lean and non-lean MAFLD patients. 
Figure 4.5: FGF21 serum levels in lean and non-lean MAFLD patients. There were no 
differences in FGF21 concentrations in lean MAFLD (253.9 ± 64.79, n = 19) compared to non-
lean MAFLD patients (310.8 ± 24.40, n = 95) (p = 0.4). Statistical differences between the 
groups were evaluated by the unpaired t test, and data shown are mean ± SEM. 
4.2.6 Clinical parameters and their correlation with FGF21 serum levels in patients with 
MAFLD 
To complete characterizing the role of FG21 in MAFLD, I next explored the correlation 
between serum levels of FGF21 and a cluster of clinical parameters and biochemical indexes 
namely; gender, height, weight, body mass index (BMI), liver enzymes (ALT, AST, GGT and 
ALP), platelets, lipid profile (cholesterol, HDL-C, LDL and triglycerides), and glycemic 
profile (presence of type 2 diabetes, fasting glucose and homeostatic model assessment of 
insulin resistance (HOMA-IR).  
4.2.6.1 FGF21 serum levels and their correlation with liver enzymes 
Aspartate Aminotransferase (AST) and Gamma-glutamyl transferase (GGT) are 
considered non-invasive markers reflecting injury and fibrosis in liver diseases [320, 321]. I 
established that there was a positive and significant correlation between FGF21 and AST (p < 
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0.01) and similarly with GGT (p < 0.05) as illustrated in Figure 4.6, but not with platelets, 
ALT and ALP. This is in line with my data that FGF21 serum levels are increased in patients 
with MASH and genetic data showing a significant association between the FGF21 rs838133 
(A) allele and hepatic inflammation. 
  
 
Figure 4. 6: FGF21 serum levels correlation with liver enzymes. 
Figure 4.6: FGF21 serum levels and their correlation with liver enzymes. There was a 
strong positive association among FGF21 serum levels and AST (R = 0.283, p = 0.003, n = 
110) (A). Similarly, there was a positive correlation between FGF21 serum levels and GGT (R 
= 0.202, p = 0.036, n = 108) (B), Statistical differences between groups were assessed by the 
Spearman correlation coefficient (** p < 0.01), (* p < 0.05) and data are expressed as R and P, 
and number of XY pairs. 
4.2.6.2 FGF21 serum levels and their correlation with metabolic parameters 
Based on recently published data on the known regulatory role of FGF21 on various 
metabolic pathways [322], I analysed the correlation between FGF21 and the glycaemic and 
lipid profile. Interestingly, we found a strong correlation between FGF21 and blood glucose (p 
< 0.001) as shown in Figure 4.7A, as well as with insulin resistance, as measured by HOMA-
A B 
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IR (p < 0.01) (Figure 4.7B). Consistently, circulating FGF21 was elevated in MAFLD patients 
with diabetes (n = 34) compared to those without (n = 76) (p < 0.05) (Figure 4.8).  
Next we explored the correlation between FGF21 and the lipid profile.  A significant 
correlation was found between FGF21 and serum triglycerides (p < 0.05) as shown in the 
Figure 4.9, but not with cholesterol, HDL-C and LDL-C.  
 
Figure 4. 7: FGF21 serum levels correlation with blood glucose and HOMA 
Figure 4.7: FGF21 serum levels and their correlation with blood glucose and HOMA-IR. 
There was a significant correlation between FGF21 serum levels and blood glucose (R = 0.330, 
p = 0.001, n = 105). There was a significant positive correlation between FGF21 serum levels 
and HOMA-IR (R = 0.260, p = 0.006, n = 111). Statistical differences between groups were 
assessed by Spearman correlation coefficient (*** p < 0.001), (** p < 0.01) and the data 
presented are as R, P and number of XY pairs.  
A 
 
B 
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Figure 4. 8: FGF21 serum levels correlation with diabetes mellitus. 
Figure 4.8: FGF21 serum levels and their correlation with diabetes mellitus. FGF21 serum 
levels in non-diabetic patients (204.6 ± 28.49, n = 76) was lower than that in those with DM 
(257.9 ± 40.86n = 34) (p = 0.03). Differences between the two groups was assessed by the 
Mann Whitney test (* p < 0.05) and the data presented are presented as median ± SEM. 
 
Figure 4. 9: Serum FGF21 and triglycerides correlation. 
Figure 4.9: Serum FGF21 and triglycerides correlation. There was a significant correlation 
between FGF21 serum levels and TG (R = 0.194, p = 0.044, n= 109). Statistical differences 
between the groups were assessed by Spearman correlation coefficient (* p < 0.05) and the data 
presented are as R, P and number of XY pairs. 
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4.2.7 Serum FGF21 levels and their correlation with bile acids 
In human, the total bile acid pool is tightly regulated by the liver through control of 
genes engaged with bile acid synthesis, secretion, reabsorption and reuptake [323]. Secondary 
bile acids are produced by intestinal microflora and contribute to the bile acid pool in humans 
[324]. FGF21 is a master regulator of glucose and lipid homeostasis in vivo and has recently 
been found to be negative regulator of bile acid synthesis [325], but the correlation between 
FGF21 and bile acids in human has not been explored. We investigated this correlation in our 
cohort of patients with MAFLD.  
Interestingly, there was a positive association between FGF21 serum levels with both 
total bile acids (p < 0.05) and total primary bile acids (p < 0.01), but not with secondary bile 
acids (Figure 4.10). In addition, there was a significant correlation between FGF21 and various 
individual bile acids as depicted in Table 4.1.  
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Figure 4. 10: Correlation of Serum FGF21 and bile acid levels.  
Figure 4.10: Correlation of serum FGF21 and bile acid levels. A significant correlation 
between serum FGF21 level and total bile acids (R = 0.245, p = 0.010, n = 111) (A) and total 
primary bile acids (R = 0.254, p = 0.006, n = 111) was found (B). There was no association 
between serum FGF21 level and total secondary BAs (R = 0.150, p = 0.116, n = 111) (C). 
Statistical differences between the groups were assessed by Spearman correlation coefficient 
(*p < 0.01), and the data are presented as R, P, and number of XY pairs.  
 
 
A B 
C 
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Table 4.1. Summary of the correlation between serum FGF21 and individual bile acids 
concentrations. 
Bile Acids R p 
Glycocholic acid 0.25 0.008 
Glycoursodeoxycholic acid 0.273 0.004 
Glycine Conjugated 0.247 0.009 
Cholic acid 0.207 0.029 
Taurochenodeoxycholic acid 0.209 0.028 
Total 6 α hydroxylated bile acids 0.233 0.014 
Taurine Conjugated 0.203 0.032 
Conjugated Cholic Acid 0.241 0.011 
Glycochenodeoxycholic acid 0.231 0.015 
Tauroursodeoxycholic acid 0.239 0.012 
Secondary primary bile acids -0.145 0.129 
Unconjugated bile acids 0.104 0.277 
Glycol-hyodeoxycholate acid -0.062 0.517 
Chenodeoxycholic acid 0.115 0.228 
Hyodeoxycholic acid -0.005 0.956 
Ursodeoxycholic acid  0.111 0.245 
Hyocholic acid 0.42 0.66 
Glycolithocholic acid -0.181 0.058 
Glycodeoxycholic acid 0.102 0.287 
Taurodeoxycholic acid  0.127 0.148 
Trichloroacetic acid 0.182 0.056 
Deoxycholic acid  -0.057 0.55 
Table 4. 1. Summary of the correlation between serum FGF21 and the individual bile acids concentrations. 
Statistical differences between the groups were assessed by Spearman correlation coefficient 
and the data are expressed as R and P, and number of XY pairs = 111). 
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4.2.8 Hepatic Fgf21 expression in a high sucrose diet mouse model 
A recent study suggests that excessive sugar intake predisposes individuals to MAFLD 
[71]. Fgf21 production is stimulated by the ingestion of either fructose or glucose via a negative 
feedback loop involving the liver and hypothalamus [326]. Thus, I next investigated hepatic 
Fgf21 expression in a high sucrose fed mouse model. To this end, mice were fed a 33% high 
sucrose diet (HS) or normal chow (NC) for 16 weeks and hepatic expression of Fgf21 was 
measured by RT-PCR. The mice developed steatosis and weight gain and hepatic Fgf21 mRNA 
relative expression was found to be increased in HS fed mice compared to normal chow (NC) 
fed mice (p < 0.05) (Figure 4.11).  
 
Figure 4. 11: Effect of high sucrose diet on hepatic Fgf21 mRNA relative expression. 
Figure 4.11: Effect of a high sucrose diet on hepatic Fgf21 mRNA relative expression. 
Hepatic Fgf21 mRNA relative expression was significantly increased by a high sucrose diet in 
a mouse mice model (4.009 ± 1.215, n = 6) compared to normal chow (NC) (1.166 ± 0.2735, 
n = 6) (p = 0.011). Statistical differences between the two groups were measured by unpaired 
t test (*p < 0.05) and the data presented are as mean ± SEM.  
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4.2.9 Fgf21 expression in mouse liver in different fibrosis models 
I next investigated the hepatic expression of Fgf21 in mouse models of inflammation 
and fibrosis, namely the methionine and choline deficient (MCD) diet and bile duct ligation 
(BDL). Consistent with my human data, the hepatic expression of Fgf21 was be upregulated 
by the MCD diet (p < 0.0001) (Figure 4.12A) and by BDL (p < 0.05) (Figure 4.12B) though 
it was more profound in the former.  
  
 
Figure 4. 12: Hepatic Fgf21 mRNA relative expression in two fibrosis mice models, MCD and BDL. 
Figure 4.12: Hepatic Fgf21 mRNA relative expression in two mouse fibrosis models. 
Fgf21 mRNA relative expression was increased in MCD diet fed (83.24 ± 6.582, n = 5) 
compared to NC fed mice (1.046 ± 0.1302, n = 6) (p < 0.0001) (A), and after BDL (10.37 ± 
3.612, n = 6) compared to sham controls (1.029 ± 0.1096, n = 6) (p = 0.027) (B). Real-time 
PCR was performed to compare between the groups. Statistical differences between the two 
groups were assessed by the unpaired t test. The significance was assumed for P values (****p 
< 0.0001), (*p < 0.05), and the data are presented as mean ± SEM. 
4.2.10 FGF23 serum level in MAFLD 
To complete characterising the role of eFGF family proteins in MAFLD, I also 
investigated changes in FGF23 serum levels in patients with MAFLD and healthy controls. 
A B 
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The bone is considered the main site of synthesis of FGF23 [185] even though the protein is 
expressed in the liver, thymus, heart, lung, muscle and spleen [162]. Interestingly, in contrast 
to FGF21, serum FGF23 levels were decreased in MAFLD compared to healthy controls (p < 
0.01) (Figure 4.13), with a non-significant trend to be attenuated in MASH compared to 
healthy controls (p < 0.05) and simple steatosis (p = 0.4) (Figure 4.14A). No difference in 
FGF23 levels was observed according to fibrosis stage (p = 0.5) (Figure 4.14B) or between 
lean and obese patients with MAFLD (p = 0.7) (Figure 4.14C). 
 
Figure 4. 13: FGF23 serum levels in MAFLD and healthy control. 
Figure 4.13: FGF23 serum levels in MAFLD and healthy controls. FGF23 serum levels 
were decreased in MAFLD patients (2547 ± 377.4, n = 83) compared to healthy controls (4630 
± 773.3, n = 32) (p = 0.008). Statistical differences between the groups were assessed by the 
unpaired t test (** p < 0.01) and the data are expressed as mean ± SEM.  
 
 
 
 
  77  
 
 
 
 
 
Figure 4. 14: FGF23 serum levels in patients with MAFLD and healthy control. 
Figure 4.14: FGF23 serum levels in patients with MAFLD and healthy controls. FGF23 
serum levels were significantly decreased in MASH patients (2969 ± 825.9, n = 15) compared 
to healthy controls (6411 ± 812.2, n = 23) (p = 0.01). No significant change was detected in 
FGF23 serum levels between healthy control and simple steatosis patients (4682 ± 1146, n = 
11) (p = 0.4) or between simple steatosis and MASH (p = 0.5) (A). The FGF21 serum level 
showed no difference between patients with fibrosis (F1-F4) (2228 ± 478, n = 48) compared to 
those without fibrosis (F0) (2733 ± 725.2, n = 27) (p = 0.5) (B). Similar to our findings with 
FGF21, there was no significant differences in FGF23 levels between lean (2782 ± 835.40, n 
= 16) and non-lean MAFLD (2491 ± 425.58, n = 67) (p = 0.7) (C).  Statistical differences 
between the groups were measured by an unpaired t test or ANOVA, as appropriate (* p < 
0.05). Multiple comparisons were corrected by Bonferroni and the data presented are mean ± 
SEM.   
A 
C 
B 
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4.2.11 Clinical parameters and their correlation with FGF23 serum levels 
I explored the correlation of FGF23 with clinical variables and found only a significant 
correlation between FGF23 serum levels and total cholesterol (Figure 4.15A) and a negative 
correlation with age (Figure 4.15B), but not with any other variables. In total, these data 
suggest that it is likely that FGF23 has a less important role in MASH compared to FGF21. 
 
 
Figure 4. 15: FGF23 serum levels correlation with clinical variables in MAFLD. 
Figure 4.15: FGF23 serum levels and their correlation with clinical variables in MAFLD. 
There was a positive association between FGF23 serum levels and cholesterol (R = 0.270, p = 
0.018, n = 75) (A). Moreover, there was a negative correlation between FGF23 serum levels 
and age (R = -0.3104, p = 0.0060, n = 77) (B). Statistical differences between the groups were 
calculated by Spearman correlation coefficient (* p < 0.05), (** p < 0.01) and the data presented 
are as R, P and number of XY pairs. 
 
 
A B 
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4.2.12 FGF21 correlation with other endocrine FGF family members (FGF19 and 
FGF23). 
Finally, I explored if there was any correlation between FGF family members (FGF19, 
FGF21 and FG23) in patients with MAFLD. No correlations were observed between the serum 
levels of the eFGFs, suggesting that even they belong to the same family it is likely that they 
are regulated by different mechanisms.  
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Figure 4.16: Correlation of serum levels of FGF family members (FGF19, FGF21 and 
FGF23) in patients with MAFLD. There was no correlation between serum FGF21 levels 
and FGF19 (R = -0.0977, p = 0.3596, n = 90) (A). Similarly, there was no correlation between 
serum FGF21 levels and FGF23 (R = -0.1945, p = 0.0991, n = 73) (B). There was a positive 
non-significant correlation between serum FGF23 levels and FGF19 (R = 0.1049, p = 0.424, n 
= 60) (C). Statistical differences between the groups were assessed by Spearman correlation 
coefficient and the data presented are as R, P and number of XY pairs.  
 
A B 
C 
Figure 4. 16: Correlation of serum levels of FGF family 
(FGF19, FGF21 and FGF23) in patients with MAFLD. 
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4.3 Discussion 
In this chapter, the role of the eFGF family and in particular FGF21 was characterised 
in as detailed an investigation as possible in cross-sectional human and complementary mouse 
studies. This study had 3 key findings: First, serum levels of FGF21 were elevated in patients 
with MAFLD when compared to healthy controls; this difference was more profound with 
progression of disease and fibrosis development; FG21 levels positively correlated with AST 
and GGT as indices of liver injury. Consistently, hepatic mRNA expression of FGF21 was 
robustly elevated in two fibrosis mouse models. Second, FGF21 had a differential impact on 
the metabolic profile as it positively correlated with fasting glucose and insulin resistance but 
not with the lipid profile. Similarly with regard to bile acids, FGF21 correlated with total and 
primary bile acids but not with secondary bile acids. Thirdly, the eFGF family (FGF19, FGF21 
and FGF23) are likely regulated by different mechanisms and likely have differential 
implications for MAFLD with a limited role for FGF23 compared to the other two members.  
While carriage of the FGF21 allele (A:rs838133) and serum FGF21 was associated 
with an increased risk of with hepatic inflammation and the transition from normal liver to 
early fibrosis, it did not impact hepatic steatosis, with similar results in mouse models. Notably, 
these effects were blunted with progression of disease. Given the known favourable metabolic 
effects of FGF21[310], an intriguing question is whether the rise in FGF21 levels is a 
compensatory response to metabolic stress or due to resistance to the metabolic effects of 
FGF21 [184]. Although, it is hard to ascertain this given the cross-sectional nature of my study, 
collectively the results imply that increased of FGF21 in the context of fatty liver disease is a 
compensatory adaptation in the early stages of steatpohepatitis. However, in the context of 
ongoing liver injury, this homeostatic response might possibly be weakened and no longer be 
able to dampen inflammation and fibrosis. This hypothesis is supported by the observed 
positive correlation between serum FGF21 levels and total and primary bile acids.  
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Long-term accumulation of bile acids within hepatocytes can cause mitochondrial 
dysfunction, endoplasmic reticulum stress, and immune cell infiltration that can ultimately 
lead to inflammation, cell death, liver injury and cancer [327-332]. In addition, bile acids 
activate hepatic stellate cells and represent an independent (direct) profibrogenic factor 
[333, 334]. Interestingly, FGF21 did not have an impact on secondary bile acids indicating that 
it impacts synthesis rather than secondary conversion.  In line with this data, a recent study 
suggests that FGF21 can negatively regulate bile acids synthesis by reducing the expression of 
two key enzymes of the bile acids synthesis pathway namely Cyp7A1 and Cyp8B1[310]. These 
findings in concert with the current results suggest that FGF21 may play a pivotal role in 
protecting from bile acids-induced toxicity. This further supports the suggestion that the 
increase in FGF21 in MASH is part of a wider compensatory adaptation response.  
The mechanisms for the protective effects of FGF21 on hepatic inflammation in MASH 
are likely multifactorial. FGF21 regulates glucose homeostasis as it improves insulin 
resistance, peripheral tissue glucose uptake and reduces serum glucose levels and increases 
adiponectin secretion; these effects result in prevention of glucotoxicity, oxidative and ER 
stress [313, 335, 336]. Of relevance, we demonstrated that serum FGF21 level was positively 
correlated with blood glucose and HOMA-IR. Moreover, a direct anti-inflammatory effect of 
FGF21 is mediated through reduction of immune cell infiltration and inhibition of the NF-Kb 
pathway in macrophages [337]. Additionally, FGF21 may oppose the pro-inflammatory effect 
of IL-1β [293]. 
The current data are consistent with another recent study showing that serum FGF21 
levels are elevated in MASH but not with steatosis [268, 338]. However, in another small study 
(n = 21), no difference in FGF21 according to presence of MASH was observed [265]. 
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Notably, no correlation between the FGF21 allele (A:rs838133) or serum FGF21 levels 
with steatosis was discerned, a finding consistent with another recent study [268]. Multiple 
hypotheses for this can be entertained. First, FGF21 might have differential impacts on hepatic 
steatosis and inflammation. Of relevance, no correlation was found between serum FGF21 level 
and the lipid profile, apart from serum triglyceride; the latter may actually be secondary to the 
FGF21 correlation with insulin resistance. Second, because any possible association might be 
weak, a larger cohort size might be required to definitively refute or confirm any effect on 
steatosis. This is relevant as Pegbelfermin (BMS-986036) a PEGylated human fibroblast 
growth factor 21 (FGF21) analogue led to a reduction in the hepatic fraction in phase 2a human 
study [252]. 
Finally, in contrast to FGF21, serum FGF23 levels were downregulated in both 
MAFLD and MASH patients with no impact on the metabolic profile. This might be explained 
by the fact that the FGF23 metabolic pathway is more specific to bone health and mineral 
homeostasis [308, 339-341]. MAFLD has been reported to be a risk factor for osteoporosis and 
chronic kidney disease independent of other confounding [342, 343] but the mechanisms for 
this are unclear.  Whether FGF23 might be the missing link between MAFLD and these extra-
hepatic manifestations would require further investigation. Interestingly, the serum levels of 
eFGF family members (FGF19, FGF21 and FGF23) were not correlated with each other 
suggesting that they are differentially regulated with each member likely having distinctive 
metabolic actions [344]. 
The strengths of this study include that it the first comprehensive characterisation of 
the role of eFGF family members in a well phenotyped patient cohort with MAFLD that 
included liver histology, glycaemic profile, lipid and bile acids levels and that is further 
supported by mouse data. However, this study also has limitations. First, as patients were 
recruited from tertiary referral centres the cohort may suffer from selection bias. In addition, 
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dietary histories were not available to enable exploration of the correlation between FGF21 and 
sugar intake. Finally, the cross-sectional design did not allow any causal relationships to be 
investigated.  
In conclusion, the various eFGF family members seem to have differential regulatory 
mechanisms and functional consequences. FGF21 level is increased with advancement of 
MAFLD and likely plays a crucial role in protection from insulin resistance and bile acids-
induced toxicity, while FGF23 might be implicated in some of the extra-hepatic 
manifestations of the disease. 
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Chapter 5: Overall Discussion 
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5.1 Summary: Future challenges and open questions 
 
MAFLD is a global emerging problem that affects a quarter of the population and is on 
trajectory to become the primary indication for liver transplantation in many countries; it thus 
represents a significant health and economic burden to society and health care systems [12, 
23]. This increase in disease burden is likely an outcome of urbanisation and the combination 
of a sedentary lifestyle coupled to inadequate physical inactivity and nutritionally imbalanced 
and unhealthy diets. The pathogenesis of the disease is complex and is likely shaped by 
dynamic gene-environment interactions.  
There is strong evidence that MAFLD has a high heritability component but to date, all 
known risk variants explain only 10-20% of this predisposition. This suggests the existence, as 
with other complex diseases, of missing heritability [261]. Recently it has been recognised that 
there is a hereditary basis to individual variation in macronutrient intake and of host genetic 
determinants of dietary intake to nutrition-related disorders [263].  In spite of strong evidence 
for a role for dietary intake in MAFLD, the role of genetic variants and their relationship to 
dietary intake remains obscure. However, a recent large study has identified the rs838133 
polymorphism in FGF21 as being implicated in sugar intake. As increased sugar consumption 
is a classic risk factor for MAFLD development and progression, it was intriguing to explore 
the role of this variant in MAFLD. In addition, the role of the eFGF family particularly FGF21 
in MAFLD is controversial and its relationship to bile acid homeostasis has not been explored. 
Based on this gap in the literature, the main aim of the current study was to delineate 
the role of the rs838133 polymorphism in MAFLD as well as to characterise the histological 
and clinical effects of FGF21 and FGF23. I also incorporated the human data with preliminary 
data from several animal models. 
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5.2 Summary of findings  
 
I have identified that FGF21 rs838133 is a novel additional gene variant affecting the 
risk of MASH. Both FGF21 rs838133 and FGF21 serum levels had more profound effects on 
inflammation and subsequently fibrosis compared to steatosis. These findings were replicated 
in two mouse models with liver injury. In addition, FGF21 had a differential impact on the 
metabolic profile with a predominant role on the glycaemic, compared to the lipid profile. 
FGF21 correlated with total and primary bile acids but not with secondary bile acid levels 
suggesting a role for FGF21 in the synthesis rather than the conversion to secondary bile acids. 
Finally, other eFGFs family proteins (FGF19 and FGF23) were not correlated in patients with 
MAFLD suggesting that they are probably controlled by different mechanisms. 
5.3 Significance of findings 
 
Nearly a quarter of the global population have MAFLD and these numbers are expected 
to rise over the next few decades. This has far-reaching implications with regard to the concept 
of leveraging the shared genetic basis of MAFLD and dietary intake to fill “missing 
heritability” and to improve our understanding of the pathogenesis of the disease. 
Understanding the functional mechanisms that link genetic variants to MAFLD can provide an 
opportunity for the development of novel therapeutic targets as recently suggested [345]. 
Although FGF21 seems to be a promising therapeutic target with multiple ongoing 
clinical trials, the results of these trials suggest a modest impact on improving MASH and 
fibrosis. This muted response is likely attributed to the marked heterogeneity of MAFLD and 
our incomplete understanding of the pathophysiological roles of FGF21. Hence, clarifying the 
genetic basis of MAFLD and of FGF21 impact can guide efforts for proper patient stratification 
while also helping to understand more efficient ways to therapeutically modulate this protein.  
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5.4 Future direction 
  
5.4.1 Determine the role of the FGF21 rs838133 variant and serum levels in other liver 
diseases  
 
My data suggested that FGF21 rs838133 is a novel risk variant for hepatic 
inflammation in patients with MAFLD. As inflammation might have similar pathways across 
different liver diseases, this variant may also play a role in other liver diseases as our unit has 
recently demonstrated for variants in IFNL3 and MBOAT7 [346, 347]. Thus, it would be 
interesting to explore if rs838133 plays a role in modulating inflammation in patients with 
hepatitis B and C infection.  
5.4.2 Determine the functional mechanism of the FGF21 rs838133 variant 
 
In this study I demonstrated that the rs838133 SNP is predicted to drastically alter 
mRNA structure. For further confirmation of this finding and for clarifying the functional 
consequences, several possible strategies can be considered: 
1. SHAPE- MaP analysis. 
2. Detecting secondary structure alterations of FGF21 mRNA by circular dichroism (CD) 
spectroscopy. 
3. Analysis of the effect of rs838133 on FGF21 mRNA half-life. 
4. Analysis of the effect of rs838133 on FGF21 translational rate. 
5.4.2.1 SHAPE- MaP analysis 
 
SHAPE-MaP reactivity is a model-free measurement of RNA structure [348, 349]. SHAPE 
data can be used to develop accurate models for large, complexly structured RNAs [350, 351]. 
The protocol for probing RNA structure in vitro uses selective 2’-hydroxyl acylation analyzed 
by primer extension and mutational profiling (SHAPE-MaP) to assess RNA structure at 
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nucleotide resolution. Modified nucleotides are detected as internal miscoding during reverse 
transcription and then read by massively parallel sequencing [352]. 
5.4.2.2 Detect secondary structure alterations of FGF21 mRNA by circular dichroism (CD) 
spectroscopy 
 
CD spectroscopy is a form of light absorption spectroscopy that measures the difference 
in absorbance of right- and left-circularly polarized light (rather than the commonly used 
absorbance of isotropic light) by a substance[353]. CD Spectroscopy can reveal structural 
differences between wild and mutant FGF21 mRNA.  
5.4.2.3 Analysis of the effect of rs838133 on FGF21 mRNA half-life. 
 
To investigate the consequences of rs838133 on mRNA “misfolding” it would be 
exciting to detect the impact of the SNP on mRNA stability. To this end, a stable cell line 
expressing either wild or mutant alleles of FGF21 needs to be treated with actinomycin D to 
inhibit transcription. RNA is then isolated at different specified time points and relative FGF21 
mRNA levels are measured by real time RT-PCR to determine the impact on half-life as 
previously done by our unit [125].  
5.4.2.2 Measurement of translational rate  
 
To test whether the enlarged single stranded loops in FGF21 mRNA alters translation 
of the mutant protein, stable cell lines expressing either the wild or mutant alleles of FGF21 
are generated and in vitro translation reactions are assessed using polysome profiling [354]. 
5.4.3 Determine the association between FGF21 rs838133 variant and serum FGF21 
levels with sugar intake in humans  
 
My data suggests that sugar intake in mice models correlates with hepatic Fgf21 mRNA 
relative expression, consistent with other evidence in the literature [326]. However, 
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corroborating evidence in humans is lacking. Therefore, it would be interesting to study this 
relationship in a cohort with available dietary history.  
5.4.4 Effects of bile acids to changes in the microbiota 
 
 In my study, FGF21 correlated with bile acid levels. Moreover, bile acids have been 
shown to impact microbiota [355, 356]. Thus, it would be interesting to explore the impact of 
the FGF21 genetic variant and serum FGF21 levels on gut microbiota composition.  
5.4.5 Determine FGF21 effects on other inflammatory and immune cells  
 
 There is a large body of evidence on the role of FGF21 in hepatocytes. My data 
demonstrated that the rs838133 A allele and FGF21 levels were associated with inflammation. 
Thus, it would be of interest to investigate the role of FGF21 in inflammatory and immune 
cells such as macrophage as they play a key role in hepatic inflammation [357] and to dissect 
the differential impacts on hepatocytes versus macrophage using conditional knockout mice 
models and in vitro systems.  
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